An Open-label, Randomized, Four-period, Crossover Study in Two Panels of Healthy Adult Subjects to Assess the Relative Bioavailability, Food Effect, and Dose-dependence of Single-dose Immediate-release and Single-dose Dispersible Formulations of Pretomanid
Phase: PHASE1
Conditions: Multi-drug Resistant Tuberculosis
Sponsor: Global Alliance for TB Drug Development

3URWRFRO3D&/9
7%$OOLDQFH
&21),'(17,$/
'HF
3DJHL

&/,1,&$/678'<35272&2/
$Q2SHQODEHO5DQGRPL]HG)RXUSHULRG&URVVRYHU6WXG\LQ7ZR3DQHOVRI+HDOWK\
$GXOW3DUWLFLSDQWVWR$VVHVVWKH5HODWLYH%LRDYDLODELOLW\)RRG(IIHFWDQG
'RVHGHSHQGHQFHRI6LQJOH'RVH,PPHGLDWH5HOHDVHDQG6LQJOHGRVH'LVSHUVLEOH
)RUPXODWLRQVRI3UHWRPDQLG
35272&2/180%(5
3D&/
9(56,21'$7(
'HF

&21),'(17,$/,7<67$7(0(17
7KHFRQILGHQWLDOLQIRUPDWLRQLQWKLVGRFXPHQWLVSURYLGHGWR\RXDVDQ,QYHVWLJDWRURU
FRQVXOWDQWIRUUHYLHZE\\RX\RXUVWDIIDQGWKHDSSOLFDEOH,QVWLWXWLRQDO5HYLHZ
%RDUG,QGHSHQGHQW(WKLFV&RPPLWWHH<RXUDFFHSWDQFHRIWKLVGRFXPHQWFRQVWLWXWHV
DJUHHPHQWWKDW\RXZLOOQRWGLVFORVHWKHLQIRUPDWLRQKHUHLQWRRWKHUVZLWKRXWZULWWHQ
DXWKRUL]DWLRQIURP:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&H[FHSWWRWKH
H[WHQWQHFHVVDU\WRREWDLQLQIRUPHGFRQVHQWIURPSHUVRQVZKRSDUWLFLSDWHDVVXEMHFWVLQ
WKLVVWXG\
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 3

&%'%%"(	(((
 
	

Na-R;MH57;Ha/5M:OKC^;:a%OXS	R;SCO:a!SOTTOZ;Sa0VX:]aCMa1[Oa.5M;HTaOU';5HVB]a:XHVa
0X7F;8VTaVOaTT;TTaVB;a/;H5VDZ;a CO5Z5CH57CHCV]a%OO:a$@;8Va5M:a"OT;
:;R;M:;M8;aO<a
0CMAH;:OT;a(KK;:C5V;
S;H;5T;a5M:a0CMAH;
:OT;a"CTR;STC7H;a%OSKXH5VCOMTaO<a.S;VOK5MC:a
.SOVO8OHa+XK7;Sa
0ROMTOSa
0ROMTOSa!OMV58Va
*;:D85Ha-=>E8;Sa
.5
!)
a
&HO75HaHIC5M8;a?QSa1 a"SYAa";Z;HORK;MVa1 aHHD5M8;a
%S5M8;Ta.5RR5Ta
1 aHHC5M8;a
a25JHa0VS;;VaVBa%HOOSa
+;[a3OSGa+3aa
.BOM;aa
a

 
0CAM5VXS;a
Ç
g¤{µÇ^p|ÇU·º¤Çc{³³p¼Ç
g¤¨f{p»­¤osÄ|¶|Å¾x²¤Ç
j¥Çk¢9Ç-Ov7:;$)ÇPgkÇ
F4*)S)*4H7ZF-GFJ2ÇnI/ÇÇQ554)6$Ç
MWOMCOa1OM]a)OK75S:Ca*#a
1 aHHC5M8;a
a25HHa0VS;;Va%HOOSa
,;[a3OSGa+3aa
.BOM;aa
%5\aa

0CAM5VXS;a

h«·Ç_q }ÆÇGªÀ­¤Ç[­ Ás¬Ç
heW.<r³³°Ä|¾¸¼ybM{¤½Ç
h¤Çl¡{=Ç , 	|w8XÇ®Ç(&>"(ÇdhlÇ
\T`KR\N42%Y!4)048"RSaK1LÇ
"5V;a
"5V;a
.SCM8CR5Ha(MZ;TVCA5VOSa
!]MVBC5aa45KOS5a
("# $(
2OSH:[C:;a!HCMC85Ha1SC5HTa$5SH]a.B5T;a0;SZC8;Ta))!a
a,$a)OORaa0XCV;aa
05MaMVOMCOa1;\5Taa
1;H;RBOM;aa
%5\aa 	

h¤u©Ç^s}?ÇV}¯¹}ÇF¿~~Ç

i¤¤f~s»±¤@s´·±Ä~Â»z­tÃ ~¦¾Ç
g§¤Çm£Ç
O|D
8X+A BÇV]lÇ
68%*K'$42L4F4E#43CUÇ
0CAM5VXS;a
	 
 
	  
(
(!!(
"5V;a
_6LP96
`a

(((
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 4

3URWRFRO3D&/9
7%$OOLDQFH
&21),'(17,$/
'HF
3DJHLLL
35272&2/6<1236,6
1DPHRI6SRQVRU&RPSDQ\7%$OOLDQFH
1DPHRIWHVWSURGXFW3UHWRPDQLG
1DPHRIDFWLYHLQJUHGLHQW3UHWRPDQLG
7LWOHRIVWXG\$Q2SHQODEHO5DQGRPL]HG)RXUSHULRG&URVVRYHU6WXG\LQ7ZR3DQHOVRI+HDOWK\
$GXOW3DUWLFLSDQWVWR$VVHVVWKH5HODWLYH%LRDYDLODELOLW\)RRG(IIHFWDQG'RVHGHSHQGHQFHRI
6LQJOH'RVH,PPHGLDWH5HOHDVHDQG6LQJOHGRVH'LVSHUVLEOH)RUPXODWLRQVRI3UHWRPDQLG
3ULQFLSDO,QYHVWLJDWRU&\QWKLD$=DPRUD0'
6WXG\&HQWHU
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&
1(/RRS6XLWH
6DQ$QWRQLR7H[DV
6WXG\SHULRGPD[LPXPGXUDWLRQIURPVFUHHQLQJWR
VWXG\H[LWGD\V
3KDVHRIGHYHORSPHQW

'XUDWLRQRIWUHDWPHQW
GD\VZLWKDIROORZXSYLVLWGD\VIROORZLQJWKHODVW
3.VDPSOHLQWKHODVWWUHDWPHQWVHVVLRQRUDIWHUGURSRXW
)RXUVLQJOHGRVHWUHDWPHQWVZLOOEHDGPLQLVWHUHGWRHDFK
VXEMHFWZLWKDGD\ZDVKRXWSHULRGEHWZHHQHDFKGRVH
1XPEHURIVLWHVHQUROOLQJVXEMHFWV
1XPEHURIHYDOXDEOHVXEMHFWVSODQQHGSDQHOVRISDUWLFLSDQWVHDFK
'LDJQRVLVDQGPDLQFULWHULDIRULQFOXVLRQ
9ROXQWHHUVZLOOEHKHDOWK\DGXOWPDOHVRUIHPDOHVWR\HDUVRIDJHLQFOXVLYH
2EMHFWLYHV
3ULPDU\2EMHFWLYH
x
7RDVVHVVWKHUHODWLYHELRDYDLODELOLW\RIWKHVLQJOHGRVHGLVSHUVLEOHIRUPXODWLRQLQWHQGHGIRU
SHGLDWULFWUHDWPHQWXVLQJWKHPJVLQJOHGRVHLPPHGLDWHUHOHDVHIRUPXODWLRQDVWKHUHIHUHQFH
6HFRQGDU\2EMHFWLYHV
x
7RGHWHUPLQHWKHIRRGHIIHFWIRUHDFKRIWKHIRUPXODWLRQV
x
7RDVVHVVWKHHIIHFWRIGRVHRQWKHELRDYDLODELOLW\RIWKHGLVSHUVLEOHSHGLDWULFIRUPXODWLRQXQGHUIHG
DQGIDVWHGFRQGLWLRQV
x
7RHYDOXDWHWKHWDVWHSHUFHSWLRQRIWKHGLVSHUVLEOHSHGLDWULFIRUPXODWLRQXQGHUIHGDQGIDVWHG
FRQGLWLRQV
x
7RHYDOXDWHWKHVKRUWWHUPVDIHW\DQGWROHUDELOLW\IRUHDFKRIWKHIRUPXODWLRQVXQGHUIHGDQGIDVWHG
FRQGLWLRQV

Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 5

3URWRFRO3D&/9
7%$OOLDQFH
&21),'(17,$/
'HF
3DJHLY
6WXG\GHVLJQRYHUYLHZ
7KLVLVDVLQJOHGRVHRSHQODEHOUDQGRPL]HGIRXUSHULRGIRXUWUHDWPHQWFURVVRYHUVWXG\LQKHDOWK\
DGXOWVXEMHFWV(DFKSDQHORIVXEMHFWVZLOOEHUDQGRPL]HGDFFRUGLQJWRWKHVDPHVHTXHQFH
SHULRG:LOOLDPVGHVLJQLQZKLFKHDFKSDUWLFLSDQWZLOOUHFHLYHIRXUVLQJOHGRVHWUHDWPHQWV6XEMHFWVLQ
3DQHOZLOOUHFHLYHDOOWUHDWPHQWVDIWHUFRQVXPLQJDQ)'$VWDQGDUGKLJKIDWKLJKFDORULHEUHDNIDVW
IROORZLQJDQRYHUQLJKWIDVWRIDWOHDVWKRXUV6XEMHFWVLQ3DQHOZLOOUHFHLYHDOOWUHDWPHQWVGLUHFWO\
IROORZLQJDQRYHUQLJKWIDVWRIDWOHDVWKRXUV7KHWZRSDQHOVZLOOEHLQYHVWLJDWHGFRQFXUUHQWO\
,QYHVWLJDWLRQDOSURGXFWVGRVDJHVDQGPRGHRIDGPLQLVWUDWLRQ
 7UHDWPHQW$UHIHUHQFH PJJLYHQDVDVLQJOHPJWDEOHWXVLQJWKHLPPHGLDWHUHOHDVH
IRUPXODWLRQRUDOO\DGPLQLVWHUHG
 7UHDWPHQW % WHVW    PJ JLYHQ DV IRXU PJ WDEOHWV XVLQJ WKH GLVSHUVLEOH SHGLDWULF
IRUPXODWLRQRUDOO\DGPLQLVWHUHG
 7UHDWPHQW&WHVW VLQJOHPJGLVSHUVLEOHWDEOHWRUDOO\DGPLQLVWHUHG
 7UHDWPHQW'WHVW VLQJOHPJGLVSHUVLEOHWDEOHWRUDOO\DGPLQLVWHUHG
6XEMHFWVLQ3DQHOZLOOEHDGPLQLVWHUHGHDFKWUHDWPHQWDERYHDIWHUDKRXURYHUQLJKWIDVWDQGD
KLJKIDWKLJKFDORULHEUHDNIDVW6XEMHFWVLQ3DQHOZLOOEHDGPLQLVWHUHGHDFKWUHDWPHQWDERYHDIWHUD
KRXURYHUQLJKWIDVW
&ULWHULDIRUHYDOXDWLRQ
3KDUPDFRNLQHWLFV
)XOOSKDUPDFRNLQHWLFSURILOHVRISUHWRPDQLGZLOOEHGHWHUPLQHGXSWRKRXUVDIWHUHDFKLQWDNHRI
SUHWRPDQLG%ORRGVDPSOHVIRUDQDO\VLVRISUHWRPDQLGFRQFHQWUDWLRQVZLOOEHGUDZQMXVWEHIRUHGUXJ
LQWDNHSUHGRVHDQGDWDQGKRXUVSRVWGRVHVDPSOHV
SHUGRVH
3ULPDU\SKDUPDFRNLQHWLFPHDVXUHVLQFOXGH7PD[&PD[$8&WDQG$8&LQI6HFRQGDU\
SKDUPDFRNLQHWLFPHDVXUHVLQFOXGHWKHUDWLRRI$8&WWR$8&LQI7.HO&O)DQG9G)
6WDWLVWLFDOVXPPDULHVIRUDJLYHQSHULRGZLOOLQFOXGHGDWDIURPDOOVXEMHFWVIRUZKRPLWZDVD
FRPSOHWHGSHULRGHYHQWKRVHZKRGRQRWFRPSOHWHDOOIRXUSHULRGV7KHSULPDU\PL[HGPRGHODQDO\VHV
IRUUHODWLYHELRDYDLODELOLW\GRVHDQGIRRGZLOOXVHDOOWKHGDWDIURPDOOFRPSOHWHGSHULRGV
'HVFULSWLYHVWDWLVWLFVZLOOEHXVHGWRVXPPDUL]HSUHWRPDQLGSODVPDFRQFHQWUDWLRQVDWHDFKVDPSOLQJ
WLPHSRLQWDQGIRUGHULYHGSODVPD3.SDUDPHWHUVDVDSSOLFDEOH6WDWLVWLFVLQFOXGHVDPSOHVL]HQ
PHDQ6'SHUFHQWDJHFRHIILFLHQWRIYDULDWLRQ&9JHRPHWULFPHDQPHGLDQPLQLPXPDQG
PD[LPXP
$OOGDWDZLOOEHOLVWHGHYHQLIQRWXVHGIRUVWDWLVWLFDOVXPPDULHVRUPRGHOEDVHGDQDO\VHV%XWGDWDWKDW
GRQRWFRPHIURPFRPSOHWHGSHULRGVZLOOEHFKDUDFWHUL]HGLQWKHOLVWLQJDVWRWKHLUGHILFLHQF\
)RUHDFKSDUWLFLSDQWSUHWRPDQLGSODVPDFRQFHQWUDWLRQWLPHGDWDZLOOEHJUDSKLFDOO\SUHVHQWHG
6LPLODUO\JUDSKVRIWKHPHDQSODVPDFRQFHQWUDWLRQWLPHSURILOHVDQGRYHUOD\JUDSKVZLWKFRPELQHG
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 6

3URWRFRO3D&/9
7%$OOLDQFH
&21),'(17,$/
'HF
3DJHY
LQGLYLGXDOSODVPDFRQFHQWUDWLRQWLPHSURILOHVZLOOEHSURGXFHG$GGLWLRQDOO\SKDUPDFRNLQHWLF
SDUDPHWHUVPD\EHH[SORUHGJUDSKLFDOO\
7KHELRDYDLODELOLW\RI[PJGLVSHUVLEOHWDEOHWVUHODWLYHWRWKHPJUHIHUHQFHWDEOHWZLOOEH
GHWHUPLQHGVHSDUDWHO\IRUHDFKSDQHOXVLQJDPL[HGPRGHOZLWKWKHORJWUDQVIRUPHG3.SDUDPHWHU
&PD[$8&WDQG$8&LQIDVUHVSRQVHYDULDEOHVHTXHQFHSHULRGDQGWUHDWPHQWDVIL[HGHIIHFWVDQG
SDUWLFLSDQWDVUDQGRPHIIHFW
7KHHIIHFWRIGRVHRQWKHUHODWLYHELRDYDLODELOLW\RIWKHGLVSHUVLEOHWDEOHWZLOOEHGHWHUPLQHGVHSDUDWHO\
IRUHDFKSDQHOXVLQJWKHVDPHPRGHODVDERYH
7KHHIIHFWRIIRRGRQWKHUHODWLYHELRDYDLODELOLW\RISUHWRPDQLGZLOOEHGHWHUPLQHGFRPSDULQJDFURVV
SDQHOVHDFKIRUPXODWLRQDQGGRVHWDNHQDIWHUHDWLQJEUHDNIDVWYHUVXVWKHVDPHIRUPXODWLRQDQGGRVH
WDNHQLQIDVWHGFRQGLWLRQVXVLQJDPL[HGPRGHOZLWKWKHORJWUDQVIRUPHG3.SDUDPHWHUDVUHVSRQVH
YDULDEOHSDQHOVHTXHQFHSHULRGWUHDWPHQWDQGSDQHOE\WUHDWPHQWLQWHUDFWLRQDVIL[HGHIIHFWVDQG
SDUWLFLSDQWDVUDQGRPHIIHFW
7KH7PD[RISUHWRPDQLGIRUHDFKRIWKHIRUPXODWLRQVZLOOEHGHVFULSWLYHO\FRPSDUHG
2WKHUVWDWLVWLFDOPRGHOVDQGRUSRSXODWLRQSKDUPDFRNLQHWLFPRGHOOLQJPD\DOVREHXVHGIRUIXUWKHUGDWD
LQWHUSUHWDWLRQ
6DIHW\
7KH,QYHVWLJDWRUZLOOHYDOXDWHVDIHW\XVLQJWKHIROORZLQJDVVHVVPHQWVSK\VLFDOH[DPLQDWLRQVYLWDOVLJQ
PHDVXUHPHQWVFOLQLFDOODERUDWRU\HYDOXDWLRQVHOHFWURFDUGLRJUDPV(&*VDQGUHSRUWHGRUREVHUYHG
DGYHUVHHYHQWV$(V6XEMHFWVZLOOEHPRQLWRUHGFRQWLQXRXVO\IRUDQ\$(VIURPWKHVLJQLQJRIWKH
LQIRUPHGFRQVHQWWKURXJKWKHHQGRIWKHVWXG\,QDGGLWLRQYLWDOVLJQVZLOOEHLQYHVWLJDWHGSULRUWRHDFK
GRVHDQGGDLO\DVZHOODVGD\VDIWHUWKHODVW3.VDPSOH(&*VZLOOEHREWDLQHGSULRUWRHDFKGRVHDQG
GD\VDIWHUWKHODVW3.VDPSOH&OLQLFDOODERUDWRU\WHVWVZLOOEHLQYHVWLJDWHGSULRUWRHDFKGRVHDQG
KRXUVSRVWGRVLQJDVZHOODVGD\VDIWHUWKHODVW3.VDPSOH6DIHW\IROORZXSLVSODQQHGGD\V
IROORZLQJWKHODVW3.VDPSOHLQWKHODVWWUHDWPHQWVHVVLRQRUDIWHUGURSRXW
(IILFDF\1RHIILFDF\HYDOXDWLRQVZLOOEHSHUIRUPHGLQWKLVVWXG\

Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 7

3URWRFRO 3D&/ 9
7%$OOLDQFH
'HF
&21),'(17,$/
3DJHYL
7$%/(2)&217(176
35272&2/$33529$/3$*( LL 
35272&2/6<1236,6  LLL 
7$%/(2)&217(176 YL 
/,672)7$%/(6 YLL 
/,672)$%%5(9,$7,216 YLLL 
 
,1752'8&7,21  
 
&OLQLFDO6WXGLHV 
 
3KDUPDFRNLQHWLFV 
 
6WXG\5DWLRQDOH 
 
2%-(&7,9(6 
 
678'<'(6,*16800$5< 
 
68%-(&76(/(&7,21 
 
,QFOXVLRQ&ULWHULD  
 
([FOXVLRQ&ULWHULD  
 
$FWLYLW\5HVWULFWLRQV  
 
&RQWUDFHSWLRQ5HTXLUHPHQWV 
 
6FUHHQLQJ 
 
678'<352&('85(6  
 
6XEMHFW$VVLJQPHQW  
 
&KHFN,Q3URFHGXUHV 
 
&RQILQHPHQW 
 
)DVWLQJ0HDOV%HYHUDJHV  
 )DVWLQJ0HDOV 
 %HYHUDJHV 
 
'UXJ$GPLQLVWUDWLRQ 
 
%ORRG6DPSOLQJ3URFHVVLQJDQG6KLSPHQW 
 
(QGRI6WXG\3URFHGXUHV 
 
6DIHW\0RQLWRULQJDQG3URFHGXUHV 
 6DIHW\± $GYHUVH(YHQWV  
 6DIHW\± &OLQLFDO/DERUDWRU\(YDOXDWLRQV 
 6DIHW\± 9LWDO6LJQV  
 6DIHW\± 3K\VLFDO([DPLQDWLRQV 
 6DIHW\± (OHFWURFDUGLRJUDPV 
 2WKHU6DIHW\0HDVXUHV 
 
$'9(56((9(176 
 
'HILQLWLRQV 
 $GYHUVH(YHQW 
 6HULRXV$GYHUVH(YHQW 
 
$WWULEXWLRQ&DXVDOLW\ 
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 8

3URWRFRO 3D&/ 9
7%$OOLDQFH
'HF
&21),'(17,$/
3DJHYLL
 
5HSRUWLQJ 
 $GYHUVH(YHQW 
 
6HULRXV$GYHUVH(YHQW5HSRUWLQJ 
 
)ROORZXSRI$GYHUVH(YHQWV 
 
3RVW7ULDO6HULRXV$GYHUVH(YHQWV  
 
&OLQLFDO/DERUDWRU\$GYHUVH(YHQWV 
 
'UXJ,QWHUDFWLRQ 
 
3UHJQDQF\ 
 
*(1(5$/&216,'(5$7,216  
 
%DVLF3ULQFLSOHV 
 
,QVWLWXWLRQDO5HYLHZ%RDUG  
 
,QIRUPHG&RQVHQW 
 
,QGLFDWLRQVIRU6XEMHFW:LWKGUDZDO  
 
7HUPLQDWLRQRIWKH6WXG\  
 
'RFXPHQWDWLRQ 
 
7ULDO0RQLWRULQJ 
 
5HLPEXUVHPHQW,QGHPQLW\DQG,QVXUDQFH  
 
3+$50$&2.,1(7,&$1$/<6,6  
 
$QDO\WLFDO0HWKRGRORJ\  
 
3KDUPDFRNLQHWLFDQG6WDWLVWLFDO$QDO\VHV  
 
)$&,/,7,(6  
 
'58*6833/,(6  
 
$'0,1,675$7,9(,668(6 
 
(9(1766&+('8/(  
 
5()(5(1&(6  
$33(1',; 3+$50$&2.,1(7,&6$03/(&2//(&7,21352&(66,1*$1'
6+,30(17,16758&7,216 
$33(1',;',9,6,212)0,&52%,2/2*<$1',1)(&7,286',6($6(72;,&,7<
7$%/( 
/,672)7$%/(6
7DEOH 
,GHQWLW\RI,QYHVWLJDWLRQDO 3URGXFWV   
7DEOH 
$FFHSWDEOH3KDUPDFRNLQHWLF6DPSOLQJ7LPH:LQGRZV  
7DEOH 
$GYHUVH(YHQW$WWULEXWLRQ&DXVDOLW\5DWLQJV  
7DEOH 
'HILQLWLRQVIRU$GYHUVH(YHQW6HYHULW\*UDGLQJV  
7DEOH 
6FKHGXOHRI$VVHVVPHQWVDQG3URFHGXUHV  
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 9

3URWRFRO3D&/9
7%$OOLDQFH
&21),'(17,$/
'HF
3DJHYLLL
/,672)$%%5(9,$7,216
$'/
DFWLYLW\RIGDLO\OLYLQJ
$(
DGYHUVHHYHQW
$/3
DONDOLQHSKRVSKDWDVH
$/7
DODQLQHWUDQVDPLQDVH
$129$
DQDO\VLVRIYDULDQFH
$67
DVSDUWDWHWUDQVDPLQDVH
$8&
DUHDXQGHUWKHSODVPDFRQFHQWUDWLRQYVWLPHFXUYH
$8&ODVW
DUHDXQGHUWKHFXUYHIURPWLPHKRXUVWRODVWTXDQWLILDEOHFRQFHQWUDWLRQ
$8&LQI
DUHDXQGHUWKHFXUYHIURPWLPHKRXUVWRLQILQLW\
%0,
ERG\PDVVLQGH[
%3
EORRGSUHVVXUH
%81
EORRGXUHDQLWURJHQ
ESP
EHDWVSHUPLQXWH
&D
FDOFLXP
&)5
&RGHRI)HGHUDO5HJXODWLRQV
&,
FRQILGHQFHLQWHUYDO
&O
FKORULGH
&ODVW
ODVWTXDQWLILDEOHGUXJFRQFHQWUDWLRQ
&O)
DSSDUHQWFOHDUDQFH
&/,$
&OLQLFDO/DERUDWRU\,PSURYHPHQW$PHQGPHQWV
FP
FHQWLPHWHUV
&PD[
PD[LPXPFRQFHQWUDWLRQ
&16
FHQWUDOQHUYRXVV\VWHP
&5)
FDVHUHSRUWIRUP
&7&$(
&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV
&<3
F\WRFKURPH3
'($
'UXJ(QIRUFHPHQW$GPLQLVWUDWLRQ
G/
GHFLOLWHU
(&*
HOHFWURFDUGLRJUDP
('7$
HWK\OHQHGLDPLQHWHWUDDFHWLFDFLG
(5
H[WHQGHGUHOHDVH
)'$
)RRGDQG'UXJ$GPLQLVWUDWLRQ
IO
IOXLG
)6+
IROOLFOHVWLPXODWLQJKRUPRQH
J
JUDPV
*&3
*RRG&OLQLFDO3UDFWLFH
+,3$$
+HDOWK,QVXUDQFH3RUWDELOLW\DQG$FFRXQWDELOLW\$FW
+,9
KXPDQLPPXQRGHILFLHQF\YLUXV
+&O
K\GURFKORULGH
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 10

3URWRFRO3D&/9
7%$OOLDQFH
&21),'(17,$/
'HF
3DJHL[
,&'
LQIRUPHGFRQVHQWGRFXPHQW
,&+
,QWHUQDWLRQDO&RXQFLOIRU+DUPRQLVDWLRQRI7HFKQLFDO5HTXLUHPHQWVIRU
3KDUPDFHXWLFDOVIRU+XPDQ8VH
,1'
,QYHVWLJDWLRQDO1HZ'UXJ
,3
,QYHVWLJDWLRQDO3URGXFW
,5
LPPHGLDWHUHOHDVH
,5%
LQVWLWXWLRQDOUHYLHZERDUG
,6)
,QYHVWLJDWRU6LWH)LOH
,8'
LQWUDXWHULQHGHYLFH
.
SRWDVVLXP
.HO
WKHHOLPLQDWLRQUDWHFRQVWDQW
NJ
NLORJUDPV
/
OLWHUV
OEV
SRXQGV
/'+
ODFWDWHGHK\GURJHQDVH
/24
OLPLWRITXDQWLWDWLRQ
P
PHWHUV
0$2,
PRQRDPLQHR[LGDVHLQKLELWRU
PD[
PD[LPXP
PJ
PLOOLJUDPV
PLQ
PLQXWHV
P,8
PLOOLLQWHUQDWLRQDOXQLWV
P/
PLOOLOLWHUV
PP+J
PLOOLPHWHURIPHUFXU\
PVHF
PLOOLVHFRQG
QRU1
QXPEHURIRFFXUUHQFHV
1D
VRGLXP
QJ
QDQRJUDPV
27&
2YHUWKHFRXQWHU
R]
RXQFHV
5%&
UHGEORRGFHOO
5/'
UHIHUHQFHOLVWHGGUXJ
USP
UHYROXWLRQVSHUPLQXWH
6$(
VHULRXVDGYHUVHHYHQW
6$3
VWDWLVWLFDODQDO\VLVSODQ
623
VWDQGDUGRSHUDWLQJSURFHGXUH
7òRUWò
WHUPLQDOHOLPLQDWLRQKDOIOLIH
7ODJ
WLPHSULRUWRWKHILUVWPHDVXUDEOHQRQ]HURFRQFHQWUDWLRQ
7ODVW
WLPHRIWKHODVWPHDVXUDEOHFRQFHQWUDWLRQ
7PD[
WLPHWRUHDFK&PD[
9G)
DSSDUHQWYROXPHRIGLVWULEXWLRQ
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 11

3URWRFRO3D&/9
7%$OOLDQFH
&21),'(17,$/
'HF
3DJH[
8'6
XULQHGUXJVFUHHQ
:%&
ZKLWHEORRGFHOOV
:&7
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV%LRDQDO\WLFDO6FLHQFHV//&
ȕK&*
EHWDKXPDQFKRULRQLFJRQDGRWURSLQ
Ȝ]RU
/DPEGD]
DSSDUHQWHOLPLQDWLRQUDWHFRQVWDQWLQWHUPLQDOSKDVH
&
GHJUHHV&HOVLXV&HQWLJUDGH


Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 12

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH

,1752'8&7,21
7%$OOLDQFHKDVGHYHORSHG WZR LQYHVWLJDWLRQDOIRUPXODWLRQV  DQG PJ
GLVSHUVLEOHWDEOHWV RI SUHWRPDQLG 3$ WKDWDUHLQWHQGHG IRUSHGLDWULFXVH,QWKH
SUHVHQWVWXG\WKHSKDUPDFRNLQHWLFV3.DQGVDIHW\RIWKHGLVSHUVLEOHIRUPXODWLRQVZLOO
EHFRPSDUHGWRWKH DSSURYHGUHIHUHQFH SUHWRPDQLG 3$  PJWDEOHW 7KLVWULDO
ZLOOEHFRQGXFWHGLQFRPSOLDQFHZLWKWKHSURWRFRO*RRG&OLQLFDO3UDFWLFH*&3DQG
DOODSSOLFDEOHUHJXODWRU\UHTXLUHPHQWV
3UHWRPDQLG LVLQGLFDWHGLQFRPELQDWLRQZLWKEHGDTXLOLQHDQGOLQH]ROLG IRUWKHWUHDWPHQW
RI H[WHQVLYHO\UHVLVWDQWSXOPRQDU\WXEHUFXORVLV;'57%DQGRI PXOWLGUXJUHVLVWDQW
SXOPRQDU\0'57%WKDWLVQRQUHVSRQVLYHWRWUHDWPHQWRUZLWKGHPRQVWUDWHG
WUHDWPHQWLQWROHUDQFH 7KHSXUSRVHRIWKHSUHVHQWVWXG\LVWRLQYHVWLJDWHSUHWRPDQLG
IRUPXODWLRQVWKDWFRXOGEH XVHGIRUWKHWUHDWPHQW RI;'57%DQGQRQUHVSRQVLYHRU
WUHDWPHQWLQWROHUDQW 0'57%LQFKLOGUHQDVSDUWRIDFRPELQDWLRQUHJLPHQWKDWZLOO
DOVRLQFOXGHEHGDTXLOLQHDQGOLQH]ROLG 7KH VDIHW\DQGSKDUPDFRNLQHWLFLQIRUPDWLRQ
EHORZLVH[FHUSWHGIURPWKH,QYHVWLJDWRU¶V%URFKXUH,% IRU3UHWRPDQLG 3$
 &OLQLFDO 6WXGLHV
7KHFOLQLFDOSURJUDPRISUHWRPDQLGKDVLQFOXGHG3KDVHVWXGLHVLQKHDOWK\YROXQWHHUV
WRHYDOXDWHWKHVDIHW\WROHUDELOLW\DQG3.RIWKLVQRYHODJHQWLQKXPDQVDVZHOODV
3KDVHWULDOVWRH[SORUHLWVP\FREDFWHULFLGDODFWLYLW\GRVHUHVSRQVH3.DQGVDIHW\LQ
VXEMHFWVZLWKQHZO\GLDJQRVHGSXOPRQDU\7%$WWKHWLPHRIWKH,%GDWDFXWRIIGDWD
0D\SUHWRPDQLGHLWKHUDORQHRUDVSDUWRIDFRPELQDWLRQUHJLPHQKDVEHHQ
XVHGLQDWOHDVWFOLQLFDOWULDOVVSRQVRUHGE\HLWKHU7%$OOLDQFHRUDQRWKHUHQWLW\LQ
PRUHWKDQVXEMHFWV7ZHQW\RQHRIWKHWULDOVDUHFRQVLGHUHGDVWKHFRUHRIWKH
SUHWRPDQLGGHYHORSPHQWDOSURJUDP6DIHW\GDWDIRUSUHWRPDQLGVXPPDUL]HGEHORZDUH
EDVHGRQVXEMHFWVIURPWULDOVLQFOXGLQJVXEMHFWVZLWKHLWKHU;'57%RU
0'57%VXEMHFWVZLWKGUXJVXVFHSWLEOH'67%DQGKHDOWK\YROXQWHHUV
,QWKHVHWULDOVSUHWRPDQLGZDVHLWKHUDGPLQLVWHUHGDORQHRUDVSDUWRIDFRPELQDWLRQ
UHJLPHQVHH$SSHQGL[LQWKH,%$GYHUVHHYHQWV$(VZHUHLGHQWLILHGIURPWKH
SRROHGVDIHW\GDWDEDVHEDVHGXSRQDV\VWHPDWLFDQGZHOOGRFXPHQWHGDSSURDFK7KH
SURILOHIRUFRPPRQ$(VYDULHGDFURVVWKHSRROLQJJURXSVPRVWOLNHO\GXHWRYDULDWLRQV
LQVXEMHFWSRSXODWLRQWKHW\SHVRIGUXJVXVHGLQWKHWUHDWPHQWUHJLPHQVDQGWKH
GXUDWLRQRIH[SRVXUH,QWKH3KDVHSRROLQZKLFKVXEMHFWVZHUHH[SRVHGWRD
VLQJOHGRVHRISUHWRPDQLGUDQJLQJIURPWRPJDQGVXEMHFWVZHUHH[SRVHG
WRUHSHDWHGGDLO\GRVHVRISUHWRPDQLGUDQJLQJIURPPJWRPJIRUXSWR
GD\VDWOHDVW$(ZDVUHSRUWHGLQRISUHWRPDQLGWUHDWHGVXEMHFWVWKHDOO
SUHWRPDQLGJURXSDQGLQRIFRQWUROVXEMHFWV7KHLQFLGHQFHRIDQ\$(ZDV
ORZHULQWKHVLQJOHGRVHSUHWRPDQLGPJJURXSWKDQLQWKHRWKHUSUHWRPDQLG
JURXSVYHUVXVDUDQJHRIWR7KHPRVWIUHTXHQWO\RI
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 13

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
VXEMHFWVUHSRUWHG$(VLQWKHDOOSUHWRPDQLG JURXSZHUHKHDGDFKH QDXVHD
GHFUHDVHGKHPRJORELQ DQGFRQWDFWGHUPDWLWLV7KH RQO\$(
LQWKHFRQWUROJURXSUHSRUWHGLQDWOHDVWRIVXEMHFWVZDVKHDGDFKHZLWKDQ
LQFLGHQFHORZHUWKDQWKDWLQWKHDOOSUHWRPDQLGJURXSYHUVXV +HDGDFKH
ZDVPRUHFRPPRQLQWKHPXOWLSOHGRVHSUHWRPDQLG!PJJURXSWKDQLQWKHRWKHU
SUHWRPDQLGJURXSVYHUVXVDUDQJHRIWR1DXVHDRFFXUUHGPRUH
IUHTXHQWO\ LQWKHVLQJOH DQGPXOWLSOHGRVHSUHWRPDQLG!PJJURXSVDQG
UHVSHFWLYHO\ WKDQLQWKHVLQJOHGRVHSUHWRPDQLGPJDQGPXOWLSOHGRVH
PJJURXSVDQG UHVSHFWLYHO\'HFUHDVHGKHPRJORELQDQGFRQWDFW
GHUPDWLWLVZHUHREVHUYHGSULPDULO\LQWKH VLQJOHGRVHSUHWRPDQLG!PJJURXS
YHUVXVIRURWKHUSUHWRPDQLGJURXSV IRU KHPRJORELQGHFUHDVHG
YHUVXVDUDQJHRIWRIRUGHUPDWLWLVFRQWDFW 7KHGHFUHDVH LQKHPRJORELQ
RFFXUUHGSULPDULO\LQWKHWKRURXJK47VWXG\ZKLFKLQYROYHGPXOWLSOHEORRGGUDZVDQG
(&*SDG DSSOLFDWLRQV
7UHDWPHQWUHODWHG$(V LGHQWLILHGIURPWKHSRROHGVDIHW\GDWDEDVHRIUHSRUWHG$(VLQ
WKH3KDVH VWXGLHVZKHUHSODFHERDUPZDVDYDLODEOHDQG3KDVH DQGFOLQLFDOVWXGLHV
ZKHUHDVWDQGDUGRIFDUH DUPZDVDYDLODEOH LQFOXGHGQDXVHDYRPLWLQJUDVKDQG
LQFUHDVHGWUDQVDPLQDVHV ,QFUHDVHGWUDQVDPLQDVHVZHUHQRWVHHQ LQ3KDVHVWXGLHVEXW
ZHUHUHSRUWHGLQVWXGLHVWKDWHQUROOHGSDWLHQWVZLWK0'57%RU;'57%ZKRKDG
PXOWLSOHFRPRUELGLWLHVDQGUHFHLYHG SUHWRPDQLGLQFRPELQDWLRQ ZLWKRWKHUDQWL
WXEHUFXORVLV GUXJV
 3KDUPDFRNLQHWLFV
,PSRUWDQWGULYHUVRI3. YDULDELOLW\DUHGRVLQJZLWKRUZLWKRXWIRRGDQG
FRDGPLQLVWUDWLRQRIPHGLFDWLRQVWKDWLQGXFH&<3$
%LRDYDLODELOLW\LQWKHIDVWHGVWDWHZDVDERXWKDOIWKDWLQWKHIHG VWDWHZKHQSUHWRPDQLG
ZDVDGPLQLVWHUHGDWWKH FOLQLFDOGRVHRIPJ
,QWKHSUHVHQFHRI ULIDPSLFLQDQGHIDYLUHQ]SUHWRPDQLGDUHDXQGHUWKHFXUYH$8&
ZDVUHGXFHGDQGUHVSHFWLYHO\6XFKVWURQJDQGPRGHUDWH&<3$ LQGXFHUV
VKRXOGEHDYRLGHGZLWKSUHWRPDQLG 1RFOLQLFDOO\VLJQLILFDQWGLIIHUHQFHVLQWKH
SKDUPDFRNLQHWLFVRISUHWRPDQLGZHUHREVHUYHGEDVHG RQVH[ERG\ZHLJKWUDFHEODFN
&DXFDVLDQRURWKHUSXOPRQDU\7%VWDWXVRUKXPDQ LPPXQRGHILFLHQF\VWDWXV+,9
VWDWXV7KHHIIHFWRIUHQDORUKHSDWLFLPSDLUPHQWRQWKH SKDUPDFRNLQHWLFVRISUHWRPDQLG
LV SUHVHQWO\XQNQRZQ EXWLVEHLQJLQYHVWLJDWHGLQWZR RQJRLQJVWXGLHV
 6WXG\5DWLRQDOH
0'5 DQG;'57% KDYHEHFRPHPRUHDQGPRUHZLGHVSUHDG7UHDWPHQW UHTXLUHV
FRPSOH[SURORQJHG UHJLPHQVZLWKVLJQLILFDQW WR[LFLW\DQGUHODWLYHO\ORZFXUHUDWHV,Q
$XJXVW )'$DSSURYHG WKHXVHRISUHWRPDQLGLQFRPELQDWLRQ ZLWKEHGDTXLOLQH
DQGOLQH]ROLG%3D/UHJLPHQ IRUWKHWUHDWPHQWRI;'57%DQGVHOHFWHGIRUPVRI
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 14

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
0'57%7KLVDOORUDOPRQWKWUHDWPHQWUHJLPHQZDVDVVRFLDWHGZLWKFXUHUDWHVRI
DSSUR[LPDWHO\DQGPDQDJHDEOHWR[LFLW\0'5DQG;'575%DUHOHVVFRPPRQ
LQFKLOGUHQLWLVH[SHFWHGWKDWWKHLULQFLGHQFHLQWKLVSRSXODWLRQZLOOLQFUHDVHGXHWR
LQFUHDVLQJWUDQVPLVVLRQRIGUXJUHVLVWDQW07EVWUDLQV7KHUHIRUHWKHUHLVDQLPSRUWDQW
XQPHWPHGLFDOQHHGWRLQYHVWLJDWHWUHDWPHQWRSWLRQVIRUGUXJUHVLVWDQWIRUPVRI7%LQ
SHGLDWULFSDWLHQWV2XUIXWXUHJRDOLVWRLQYHVWLJDWHWKH%3D/UHJLPHQLQFKLOGUHQZLWK
0'5DQG;'57%7KHSUHVHQWWULDOLVGHVLJQHGWRLQYHVWLJDWHSUHWRPDQLG
IRUPXODWLRQVLQWHQGHGIRUSHGLDWULFXVH
3UHWRPDQLGLVSURYLGHGIRUDGXOWVDVDQLPPHGLDWHUHOHDVHWDEOHWZLWKPJDFWLYH
VXEVWDQFH7KHVDPHSURGXFWLVIRUHVHHQIRUDGROHVFHQWV\HDUVDQGROGHU)RU
SDWLHQWV\RXQJHUWKDQ\HDUVGLVSHUVLEOHVFRUHGWDEOHWVFRQWDLQLQJDQGPJ
SUHWRPDQLGDUHFXUUHQWO\EHLQJGHYHORSHGZKLFKZRXOGEHXVHGWRDGMXVWGRVHVEDVHG
RQERG\ZHLJKW
$QH[WUDSRODWLRQDSSURDFKLVLQWHQGHGIRUWKHSHGLDWULFFOLQLFDOGHYHORSPHQWSURJUDP
7KLVZLOOEHEDVHGRQWKHLGHQWLILFDWLRQRIGRVHVLQFKLOGUHQ\LHOGLQJH[SRVXUHWR
SUHWRPDQLGWKDWFRUUHVSRQGVWRWKHH[SRVXUHLQDGXOWSDWLHQWVZKHUHHIILFDF\KDVEHHQ
GHPRQVWUDWHG
7KLVVWXG\ZLOOHYDOXDWHWKHUHODWLYHELRDYDLODELOLW\RIWKHGLVSHUVLEOHWDEOHWFRPSDUHGWR
WKDWRIWKHLPPHGLDWHUHOHDVHWDEOHWXVHGIRUGRVLQJRIDGROHVFHQWVDQGDGXOWV,Q
DGGLWLRQDSRWHQWLDOIRRGHIIHFWZLOOEHHYDOXDWHG7KLVVWXG\ZLOOEHFRQGXFWHGLQ
KHDOWK\DGXOWYROXQWHHUV

2%-(&7,9(6
3ULPDU\2EMHFWLYH
x 7RDVVHVVWKHUHODWLYHELRDYDLODELOLW\RIWKHVLQJOHGRVHGLVSHUVLEOHIRUPXODWLRQ
LQWHQGHGIRUSHGLDWULFWUHDWPHQWXVLQJWKHPJVLQJOHGRVHLPPHGLDWHUHOHDVH
IRUPXODWLRQDVWKHUHIHUHQFH
6HFRQGDU\2EMHFWLYHV
x 7RGHWHUPLQHWKHIRRGHIIHFWIRUHDFKRIWKHIRUPXODWLRQV
x 7RDVVHVVWKHHIIHFWRIGRVHRQWKHELRDYDLODELOLW\RIWKHGLVSHUVLEOHSHGLDWULF
IRUPXODWLRQXQGHUIHGDQGIDVWHGFRQGLWLRQV
x 7RHYDOXDWHWKHWDVWHSHUFHSWLRQRIWKHGLVSHUVLEOHSHGLDWULFIRUPXODWLRQXQGHUIHG
DQGIDVWHGFRQGLWLRQV
x 7RHYDOXDWHWKHVKRUWWHUPVDIHW\DQGWROHUDELOLW\IRUHDFKRIWKHIRUPXODWLRQV
XQGHUIHGDQGIDVWHGFRQGLWLRQV
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 15

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH

678'<'(6,*16800$5<
(DFKSDQHORI VXEMHFWV ZLOOEHUDQGRPL]HGDFFRUGLQJWRWKHVDPHVHTXHQFH
SHULRG:LOOLDPVGHVLJQLQZKLFKHDFKSDUWLFLSDQWZLOOUHFHLYHIRXU VLQJOHGRVH
WUHDWPHQWV 6XEMHFWVLQ3DQHOZLOOUHFHLYHDOOWUHDWPHQWVDIWHUFRQVXPLQJ DQ)'$
VWDQGDUGKLJKIDWKLJKFDORULHEUHDNIDVWIROORZLQJDQRYHUQLJKWIDVWRIDWOHDVW
KRXUV6XEMHFWVLQ3DQHO ZLOOUHFHLYHDOOWUHDWPHQWVGLUHFWO\IROORZLQJDQRYHUQLJKW
IDVWRIDWOHDVWKRXUV 7KHWZRSDQHOVZLOOEHLQYHVWLJDWHGFRQFXUUHQWO\ )LJXUH
VKRZVWKH WULDOVFKHPDWLF
)LJXUH
7ULDO6FKHPDWLF
6HVVLRQ,
'D\V
'D\V
6HVVLRQ,,
'D\V
'D\V
3DQHO
7UHDWPHQW$%&RU'VLQJOH GRVHZLWK
EUHDNIDVW
RU
3DQHO
7UHDWPHQW$%&RU'DIWHUDKRXURYHUQLJKW
IDVW
GD\EUHDN
3DQHO
7UHDWPHQW$%&RU'
VLQJOHGRVHZLWKEUHDNIDVW
RU
3DQHO
7UHDWPHQW$%&RU'DIWHUD
KRXURYHUQLJKW IDVW
GD\EUHDN
6HVVLRQ,,,
'D\V
'D\V
6HVVLRQ,9
'D\V
)ROORZXS9LVLW
'D\
3DQHO
7UHDWPHQW$%&RU'VLQJOHGRVHZLWK
EUHDNIDVW
RU
3DQHO
7UHDWPHQW$%&RU'DIWHUDKRXURYHUQLJKW
IDVW
GD\EUHDN
3DQHO 
7UHDWPHQW$%&RU'
VLQJOHGRVHZLWKEUHDNIDVW
RU
3DQHO
7UHDWPHQW$%&RU'DIWHUD
KRXU RYHUQLJKWIDVW
GD\VDIWHUODVW
3.VDPSOHLQ
6HVVLRQ,9
7KHVFUHHQLQJ SHULRGZLOO EHJLQZLWKLQ GD\V RIWKHILUVWSDUWLFLSDQWEHLQJGRVHG
6XEMHFWVZLOOEHDVVLJQHGQXPEHUVLQDQDVFHQGLQJRUGHUEDVHGRQVXFFHVVIXO
FRPSOHWLRQRIWKHVFUHHQLQJSURFHVV
6XEMHFWVZLOOUHFHLYHDVLQJOHGRVHRIHDFKWUHDWPHQWOLVWHGLQ 7DEOH LQUDQGRPL]HG
IDVKLRQGXULQJWKHIRXU WUHDWPHQWSHULRGV
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 16

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
7DEOH ,GHQWLW\RI,QYHVWLJDWLRQDO3URGXFWV
5HIHUHQFH 3URGXFW
7UHDWPHQW$
3UHWRPDQLG3$
Dose = [PJWDEOHWXVLQJWKHLPPHGLDWHUHOHDVHIRUPXODWLRQ
RUDOO\DGPLQLVWHUHG
7%$OOLDQFH
7HVW 3URGXFW
7UHDWPHQW%
3UHWRPDQLG3$
'RVH [PJ GLVSHUVLEOH WDEOHWV PJWRWDORUDOO\
DGPLQLVWHUHG DVGLVSHUVLRQLQZDWHU
7%$OOLDQFH
7HVW3URGXFW
7UHDWPHQW&
3UHWRPDQLG3$
'RVH [PJGLVSHUVLEOHWDEOHWRUDOO\DGPLQLVWHUHG DVGLVSHUVLRQ
LQZDWHU
7%$OOLDQFH
7HVW3URGXFW
7UHDWPHQW'
3UHWRPDQLG3$
'RVH [PJGLVSHUVLEOHWDEOHWRUDOO\DGPLQLVWHUHG DVGLVSHUVLRQ
LQZDWHU
7%$OOLDQFH
(DFKVWXG\WUHDWPHQW DGPLQLVWUDWLRQZLOOEHVHSDUDWHGE\DZDVKRXWSHULRGRI GD\V
$QRXWSDWLHQW VDIHW\IROORZXS YLVLW LVSODQQHGDSSUR[LPDWHO\  GD\VIROORZLQJWKHODVW
SKDUPDFRNLQHWLF VDPSOHLQWKHODVWWUHDWPHQWSHULRGRU DIWHUGURSRXW
'XULQJHDFKVWXG\SHULRG P/ EORRGVDPSOHVZLOOEHREWDLQHGEHIRUH VWXG\GUXJ
DGPLQLVWUDWLRQDQGDWVHOHFWHGWLPHVWKURXJK KRXUVDIWHU VWXG\GUXJ DGPLQLVWUDWLRQ
$WRWDORI SKDUPDFRNLQHWLFEORRGVDPSOHVZLOOEHFROOHFWHGIURP HDFKVXEMHFW
 VDPSOHVLQHDFKVWXG\SHULRG3ODVPDSKDUPDFRNLQHWLFVDPSOHV ZLOOEHDQDO\]HGIRU
SUHWRPDQLGXVLQJDYDOLGDWHGDQDO\WLFDOPHWKRG$SSURSULDWHSKDUPDFRNLQHWLF
SDUDPHWHUVZLOOEHFDOFXODWHGIRUHDFKIRUPXODWLRQXVLQJQRQFRPSDUWPHQWDOPHWKRGV
)RRG DQGZDWHUFRQVXPSWLRQZLOOIROORZWKHJXLGHOLQHV LQ 6HFWLRQ  6XEMHFWVZKR
ZLWKGUDZIURPWKHVWXG\ZLOOQRW EHUHSODFHG

68%-(&76(/(&7,21

,QFOXVLRQ&ULWHULD
$OO YROXQWHHUVPXVWVDWLVI\WKHIROORZLQJFULWHULDWREHFRQVLGHUHGIRUVWXG\
SDUWLFLSDWLRQ
 9ROXQWDULO\FRQVHQWV WRSDUWLFLSDWHLQWKLVVWXG\ DQGSURYLGHV ZULWWHQ LQIRUPHG
FRQVHQW EHIRUH WKH VWDUWRIDQ\VWXG\VSHFLILFSURFHGXUHV
 0DOHRUIHPDOH)HPDOHVPXVWQRWEHSUHJQDQWRUEUHDVWIHHGLQJ
 :LOOLQJDQGDEOHWRFRPSO\ZLWKWKHFRQWUDFHSWLRQUHTXLUHPHQWVVHH 6HFWLRQ 
 %HWZHHQ DQG \HDUVRIDJHLQFOXVLYH DWWKHWLPHRIVFUHHQLQJ
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 17

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
 %RG\PDVVLQGH[%0,EHWZHHQDQGNJPLQFOXVLYHDQGZHLJKVD
PLQLPXPRINJ
 :LOOLQJDQGDEOHWRUHPDLQLQWKHVWXG\XQLWIRUWKHHQWLUHFRQILQHPHQWSHULRGDQG
UHWXUQIRUWKHRXWSDWLHQWIROORZXSYLVLW
 :LOOLQJDQGDEOHWRFRQVXPHWKHHQWLUHKLJKFDORULHKLJKIDWEUHDNIDVWPHDOLQWKH
WLPHIUDPHUHTXLUHGGXULQJWKHGHVLJQDWHGVWXG\SHULRG
 :LOOLQJDQGDEOHWRFRPSO\ZLWKWKHSURWRFRODQGWKHDVVHVVPHQWVWKHUHLQ
LQFOXGLQJDOOUHVWULFWLRQV

([FOXVLRQ&ULWHULD
9ROXQWHHUVZLOOEHH[FOXGHGIURPVWXG\SDUWLFLSDWLRQIRUDQ\RIWKHIROORZLQJ
 +LVWRU\RUSUHVHQFHRIFOLQLFDOO\VLJQLILFDQWFDUGLRYDVFXODUSXOPRQDU\KHSDWLF
UHQDOKHPDWRORJLFJDVWURLQWHVWLQDOHQGRFULQHLPPXQRORJLFGHUPDWRORJLF
QHXURORJLFRQFRORJLFRUSV\FKLDWULFGLVHDVHRUDQ\RWKHUFRQGLWLRQWKDWLQWKH
RSLQLRQRIWKH,QYHVWLJDWRUZRXOGMHRSDUGL]HWKHVDIHW\RIWKHVXEMHFWRUWKH
YDOLGLW\RIWKHVWXG\UHVXOWV
 $FOLQLFDOO\VLJQLILFDQWDEQRUPDOILQGLQJRQWKHSK\VLFDOH[DPLQDWLRQPHGLFDO
KLVWRU\HOHFWURFDUGLRJUDP(&*RUFOLQLFDOODERUDWRU\UHVXOWV
 9LWDOVLJQVDWVFUHHQLQJPHDVXUHGVLWWLQJDIWHUDPLQLPXPPLQXWHVUHVWDV
IROORZVEORRGSUHVVXUHLVOHVVWKDQPP+JRUJUHDWHUWKDQPP+JRU
DKHDUWUDWHORZHUWKDQESPRUKLJKHUWKDQESP2XWRIUDQJHYLWDOVLJQV
PD\EHUHSHDWHGRQFH
 +LVWRU\RUSUHVHQFHRIDOOHUJLFRUDGYHUVHUHVSRQVHWRSUHWRPDQLGRUUHODWHGGUXJV
 2QDVLJQLILFDQWO\DEQRUPDOGLHWGXULQJWKHZHHNVSUHFHGLQJWKHILUVWGRVHRI
VWXG\PHGLFDWLRQ
 3DUWLFLSDWLRQLQDQRWKHUFOLQLFDOWULDOUDQGRPL]HGVXEMHFWVRQO\ZLWKLQGD\V
EHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQ
 8VHRIDQ\RYHUWKHFRXQWHU27&PHGLFDWLRQLQFOXGLQJQXWULWLRQDORUGLHWDU\
VXSSOHPHQWVKHUEDOSUHSDUDWLRQVRUYLWDPLQVZLWKLQGD\VEHIRUHWKHILUVWGRVH
RIVWXG\PHGLFDWLRQXQWLOWKHHQGRIVWXG\YLVLWZLWKRXWHYDOXDWLRQDQGDSSURYDO
E\WKH,QYHVWLJDWRU8SWRJUDPVSHUGD\RIDFHWDPLQRSKHQLVDOORZHGDWWKH
GLVFUHWLRQRIWKH,QYHVWLJDWRUSULRUWRGRVLQJ
 8VHRIDQ\SUHVFULSWLRQPHGLFDWLRQH[FHSWKRUPRQDOFRQWUDFHSWLYHRUKRUPRQDO
UHSODFHPHQWWKHUDS\IURPGD\VEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQXQWLO
WKHHQGRIVWXG\YLVLWZLWKRXWHYDOXDWLRQDQGDSSURYDOE\WKH,QYHVWLJDWRU
 8VHRIDQ\GUXJVRUVXEVWDQFHVNQRZQWRORZHUWKHVHL]XUHWKUHVKROG
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 18

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
 8VHRIDQ\GUXJVRUWUHDWPHQWZLWKDQ\NQRZQGUXJVWKDWDUHPRGHUDWHRUVWURQJ
LQGXFHUVRULQKLELWRUVRIF\WRFKURPH3&<3HQ]\PHVHJEDUELWXUDWHV
SKHQRWKLD]LQHVFLPHWLGLQHFDUEDPD]HSLQHDQGRU3JSLQFOXGLQJ6W-RKQ¶V
:RUWZLWKLQGD\VEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQDQGWKDWLQWKH
,QYHVWLJDWRU¶VMXGJPHQWPD\LPSDFWVXEMHFWVDIHW\RUWKHYDOLGLW\RIWKHVWXG\
UHVXOWV
 )HPDOHZLWKDSRVLWLYHSUHJQDQF\WHVWUHVXOW
 3RVLWLYHXULQHVFUHHQIRUGUXJVRIDEXVHDPSKHWDPLQHVEDUELWXUDWHV
EHQ]RGLD]HSLQHVFRFDLQHFDQQDELQRLGVRSLDWHVRUFRWLQLQH
 3RVLWLYHWHVWIRUKHSDWLWLV%VXUIDFHDQWLJHQKHSDWLWLV&DQWLERG\RUKXPDQ
LPPXQRGHILFLHQF\YLUXV+,9DWVFUHHQLQJRUKDVEHHQSUHYLRXVO\WUHDWHGIRU
KHSDWLWLV%KHSDWLWLV&RU+,9LQIHFWLRQ
 +HPRJORELQJG/
 $/7RU$67![WKHXSSHUOLPLWRIQRUPDO8/1
 +\SHUELOLUXELQHPLD![8/1
 6XUJHU\ZLWKLQWKHSDVWGD\VSULRUWRGRVLQJDVGHWHUPLQHGE\WKH,QYHVWLJDWRU
WREHFOLQLFDOO\UHOHYDQW
 +LVWRU\RUSUHVHQFHRIDOFRKROLVPRUGUXJDEXVHZLWKLQWKHSDVW\HDUVDV
GHWHUPLQHGE\WKH,QYHVWLJDWRUWREHFOLQLFDOO\UHOHYDQW
 $Q\FOLQLFDOO\VLJQLILFDQWHOHFWURFDUGLRJUDPDEQRUPDOLW\DW6FUHHQLQJDVGHHPHG
E\GHFLVLRQRIWKH,QYHVWLJDWRUDQGWKH6WXG\6SRQVRU¶V0HGLFDO0RQLWRU
1RWH7KHIROORZLQJPD\EHFRQVLGHUHGQRWFOLQLFDOO\VLJQLILFDQWZLWKRXW
FRQVXOWLQJWKH6SRQVRU¶V0HGLFDO0RQLWRU
D 0LOGILUVWGHJUHH$9EORFN35LQWHUYDOVHF
E 5LJKWRUOHIWD[LVGHYLDWLRQ
F ,QFRPSOHWHULJKWEXQGOHEUDQFKEORFN
G ,VRODWHGOHIWDQWHULRUIDVFLFXODUEORFNOHIWDQWHULRUKHPLEORFNLQ\RXQJHUDWKOHWLF
SDUWLFLSDQWV
 47F)LQWHUYDO!PVHFIRUPDOHVRU!PVHFIRUIHPDOHVDWVFUHHQLQJ
'D\RU'D\SUHGRVHRUKLVWRU\RISURORQJHG47V\QGURPH
 )DPLO\KLVWRU\RI/RQJ476\QGURPHRUVXGGHQGHDWKZLWKRXWDSUHFHGLQJ
GLDJQRVLVRIDFRQGLWLRQWKDWFRXOGEHFDXVDWLYHRIVXGGHQGHDWKVXFKDVNQRZQ
FRURQDU\DUWHU\GLVHDVHFRQJHVWLYHKHDUWIDLOXUHRUWHUPLQDOFDQFHU
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 19

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH

$FWLYLW\5HVWULFWLRQV

6XEMHFWPXVWQRWGRQDWHEORRGIURPGD\VRUSODVPDIURPGD\VSULRUWRWKH
ILUVWGRVHRIVWXG\PHGLFDWLRQXQWLODIWHUIROORZXSSKRQHFDOO,WLVUHFRPPHQGHG
WKDWEORRGSODVPDGRQDWLRQVQRWEHPDGHIRUDWOHDVWGD\VDIWHUGLVFKDUJHIURP
WKHFOLQLF

6XEMHFWPXVWQRWXVHWREDFFRRUQLFRWLQHFRQWDLQLQJSURGXFWVLQFOXGLQJVPRNLQJ
FHVVDWLRQSURGXFWVIURPPRQWKVSULRUWRWKHILUVWGRVHRIVWXG\PHGLFDWLRQXQWLO
DIWHUWKHIROORZXSSKRQHFDOO

6XEMHFWPXVWQRWFRQVXPHDOFRKROIURPKRXUVSULRUWRWKHILUVWGRVHRIVWXG\
PHGLFDWLRQXQWLODIWHUGLVFKDUJHIURPWKHFOLQLF

6XEMHFWPXVWQRWFRQVXPHEHYHUDJHVRUIRRGVWKDWFRQWDLQJUDSHIUXLWRU0DQGDULQ
RUDQJHVIURPGD\VEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQRUSRSS\VHHGV
EURFFROL%UXVVHOVVSURXWVSRPHJUDQDWHVWDUIUXLWRUFDIIHLQH[DQWKLQHIURP
KRXUVEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQXQWLODIWHUGLVFKDUJHIURPWKH
FOLQLF3DUWLFLSDQWVZLOOEHLQVWUXFWHGQRWWRFRQVXPHDQ\RIWKHDERYHSURGXFWV
KRZHYHUDOORZDQFHIRUDQLVRODWHGVLQJOHLQFLGHQWDOFRQVXPSWLRQPD\EH
HYDOXDWHGDQGDSSURYHGE\WKHVWXG\,QYHVWLJDWRUEDVHGRQWKHSRWHQWLDOIRU
LQWHUDFWLRQZLWKWKHVWXG\GUXJ

6XEMHFWPXVWQRWHQJDJHLQVWUHQXRXVH[HUFLVHIURPKRXUVSULRUWRWKHILUVWGRVH
RIVWXG\PHGLFDWLRQXQWLODIWHUGLVFKDUJHIURPWKHFOLQLF

0DOHVXEMHFWVPXVWQRWGRQDWHVSHUPWKURXJKRXWWUHDWPHQWDQGIRUDWOHDVW
ZHHNVDIWHUWKHODVWGRVHRIWULDOPHGLFDWLRQRUGLVFRQWLQXDWLRQIURPWULDO
PHGLFDWLRQLQFDVHRISUHPDWXUHGLVFRQWLQXDWLRQ

&RQWUDFHSWLRQ5HTXLUHPHQWV
)HPDOHVXEMHFWVPXVWSODQQRWWRFRQFHLYHWKURXJKRXWWUHDWPHQWDQGIRUDWOHDVWZHHN
DIWHUWKHODVWGRVHRIWULDOPHGLFDWLRQRUGLVFRQWLQXDWLRQIURPWULDOPHGLFDWLRQLQFDVHRI
SUHPDWXUHGLVFRQWLQXDWLRQ
0DOHVXEMHFWVPXVWSODQQRWWRFRQFHLYHRUGRQDWHVSHUPWKURXJKRXWWUHDWPHQWDQGIRU
DWOHDVWZHHNVDIWHUWKHODVWGRVHRIWULDOPHGLFDWLRQRUGLVFRQWLQXDWLRQIURPWULDO
PHGLFDWLRQLQFDVHRISUHPDWXUHGLVFRQWLQXDWLRQ
6XEMHFWVPXVWEHRIQRQFKLOGEHDULQJSRWHQWLDOGHILQHGDV
x 0DOHRUIHPDOHVXEMHFWVLVQRWKHWHURVH[XDOO\DFWLYHRUSUDFWLFHVVH[XDO
DEVWLQHQFH
x )HPDOHVXEMHFWVRUPDOHVXEMHFWVZLWKDIHPDOHVH[XDOSDUWQHUELODWHUDO
RRSKRUHFWRP\ELODWHUDOWXEDOOLJDWLRQDQGRUK\VWHUHFWRP\
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 20

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
x )HPDOHVXEMHFWVSRVWPHQRSDXVDOZLWKDPHQRUUKHDIRUDWOHDVW\HDUSULRUWRWKH
ILUVWGRVHZLWKVHUXPIROOLFOHVWLPXODWLQJKRUPRQH)6+OHYHOVFRQVLVWHQWZLWK
SRVWPHQRSDXVDOVWDWXVDWVFUHHQLQJ
x 0DOHVXEMHFWRUIHPDOHSDUWLFLSDQWPDOHVH[XDOSDUWQHU±YDVHFWRPL]HGRUKDVKDG
ELODWHUDORUFKLGHFWRP\PLQLPDOO\WKUHHPRQWKVSULRUWRVFUHHQLQJ
2U
%HZLOOLQJWRXVHDQHIIHFWLYHPHWKRGRIELUWKFRQWUROGHILQHGDV
x 0DOHVXEMHFWVZLWKDIHPDOHVH[XDOSDUWQHUGRXEOHEDUULHUPHWKRGRUKRUPRQH
EDVHGFRQWUDFHSWLYHVRUDQLQWUDXWHULQHGHYLFHIRUWKHIHPDOHSDUWQHU
x )HPDOHVXEMHFWVGRXEOHEDUULHUPHWKRGZKLFKFDQLQFOXGHDPDOHFRQGRP
GLDSKUDJPFHUYLFDOFDSRUIHPDOHFRQGRPRU
x )HPDOHVXEMHFWVEDUULHUPHWKRGFRPELQHGZLWKKRUPRQHEDVHGFRQWUDFHSWLYHVRU
DQLQWUDXWHULQHGHYLFH
1RWH+RUPRQHEDVHGFRQWUDFHSWLRQDORQHPD\QRWEHUHOLDEOHZKHQWDNLQJWKHVWXG\
GUXJVWKHUHIRUHKRUPRQHEDVHGFRQWUDFHSWLYHVDORQHFDQQRWEHXVHGE\IHPDOH
VXEMHFWVWRSUHYHQWSUHJQDQF\

6FUHHQLQJ
7KHLQIRUPHGFRQVHQWGRFXPHQWVZLOOEHGLVFXVVHGZLWKHDFKSRWHQWLDOSDUWLFLSDQWDQG
HDFKLQGLYLGXDOZLOOVLJQDQLQIRUPHGFRQVHQWGRFXPHQWIRUWKHVWXG\EHIRUHDQ\
VWXG\VSHFLILFSURFHGXUHVEHLQJSHUIRUPHG
(DFKSRWHQWLDOVWXG\SDUWLFLSDQWZLOOKDYHWKHIROORZLQJDVVHVVPHQWVE\WKH,QYHVWLJDWRU
RUGHVLJQHHZLWKLQGD\VEHIRUHVWXG\VWDUW
x 0HGLFDOKLVWRU\DQGGHPRJUDSKLFGDWDLQFOXGLQJVH[DJHUDFHHWKQLFLW\
ERG\ZHLJKWNJKHLJKWFP%0,NJPDQGVPRNLQJKDELWV
x 3K\VLFDOH[DPLQDWLRQ
x 9LWDOVLJQV
x (&*
x &OLQLFDOODERUDWRU\WHVWV
x 6HURORJ\WHVWV
x 8ULQHWHVWIRUGUXJVRIDEXVHDOFRKRODQGFRWLQLQH
x 6HUXPSUHJQDQF\WHVWDOOIHPDOHVXEMHFWV
x )6+WHVW3RVWPHQRSDXVDOIHPDOHV
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 21

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
2QO\PHGLFDOO\KHDOWK\VXEMHFWVZLWKFOLQLFDOO\DFFHSWDEOHODERUDWRU\SURILOHVDQG(&*V
ZLOOEHHQUROOHGLQWKHVWXG\

678'<352&('85(6

6XEMHFW$VVLJQPHQW
7ZRSDQHOVRIKHDOWK\PDOH DQGIHPDOHVXEMHFWV SDUWLFLSDQWVSHUSDQHO ZLOOEH
GRVHGLQWKLVVWXG\7KHVDPSOHVL]HLVQRWEDVHGRQVWDWLVWLFDOFRQVLGHUDWLRQV7KH
QXPEHURIVXEMHFWVSODQQHGIRUHQUROOPHQWLV FRQVLGHUHG VXIILFLHQWWRDFKLHYHWKHVWXG\
REMHFWLYHV
6XEMHFWVZLOOEHUDQGRPL]HGWRDSDQHODQGWKH WZRSDQHOVZLOOEHLQYHVWLJDWHG
FRQFXUUHQWO\$GGLWLRQDOO\ VXEMHFWVLQHDFKSDQHOZLOOEHUDQGRPL]HGDFFRUGLQJWRWKH
VDPHVHTXHQFHSHULRG:LOOLDPVGHVLJQLQZKLFKHDFKSDUWLFLSDQWZLOOUHFHLYHIRXU
VLQJOHGRVHWUHDWPHQWV
7KHPD[LPXPGXUDWLRQRIWKHVWXG\IURPVFUHHQLQJWRVWXG\H[LWZLOOEH DSSUR[LPDWHO\
 GD\V
7KLVLVDQRSHQODEHOVWXG\ZLWKRXWWUHDWPHQWEOLQGLQJ

&KHFN,Q3URFHGXUHV
$W FOLQLF FKHFNLQ 'D\ DOO VXEMHFWVZLOOEH HYDOXDWHGWR FRQILUPWKH\FRQWLQXH WR
PHHWDOOWKH LQFOXVLRQFULWHULD6HFWLRQDQGQRQHRIWKH H[FOXVLRQ FULWHULD
6HFWLRQ 
$XULQHVDPSOHZLOOEHFROOHFWHGIURPDOOVXEMHFWVDWVWXG\FKHFNLQWRVFUHHQIRUGUXJV
RIDEXVHFRWLQLQHDQGDOFRKRO,IDWDQ\WLPHDQDOFRKROGUXJRUFRWLQLQH WHVWLV
SRVLWLYHWKHVXEMHFWZLOOEHGLVFRQWLQXHGIURPVWXG\SDUWLFLSDWLRQ
6XEMHFWVRIFKLOGEHDULQJSRWHQWLDOZLOOEHDVNHGWRFRQILUPWKDW WKH\VWLOODGKHUHWRWKH
FRQWUDFHSWLYHFULWHULD 6HFWLRQ(DFK VXEMHFW¶V UHVSRQVH ZLOOEHGRFXPHQWHG
$ EORRG VDPSOHZLOOEHFROOHFWHGIURPDOOIHPDOHVXEMHFWVIRUDVHUXP SUHJQDQF\WHVW
7KLVWHVWPXVWEHQHJDWLYHIRUWKHVXEMHFWWRFRQWLQXHVWXG\SDUWLFLSDWLRQ
$QDEEUHYLDWHGSK\VLFDOH[DPLQDWLRQ ZLOOEHSHUIRUPHG LQFOXGLQJPHDVXUHPHQWRI
ZHLJKW
%ORRGDQGXULQHZLOOEHFROOHFWHGIRUFOLQLFDOODERUDWRU\WHVWVKHPDWRORJ\FKHPLVWU\
DQGXULQDO\VLV
9LWDOVLJQVEORRGSUHVVXUHSXOVHWHPSHUDWXUHUHVSLUDWLRQUDWHDQGSXOVHR[LPHWU\
ZLOOEHPHDVXUHGDQGDVLQJOHOHDG(&*SHUIRUPHG
$Q\FKDQJHVWRPHGLFDOKLVWRU\DQGRUFRQFRPLWDQWPHGLFDWLRQZLOOEHUHFRUGHG
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 22

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH

&RQILQHPHQW
6XEMHFWVZLOOEHDGPLWWHGWRWKHUHVHDUFKFHQWHUDWDQDSSURSULDWHWLPHWKHGD\EHIRUHWKH
ILUVWVWXG\GUXJDGPLQLVWUDWLRQLQRUGHUWRHQVXUHDPLQLPXPKRXURYHUQLJKWIDVW
6XEMHFWVZLOOEHFRQILQHGLQWKHIDFLOLW\IURPFKHFNLQ'D\XQWLOFRPSOHWLRQRIWKH
GD\SRVWGRVHSURFHGXUHVLQ3HULRG6WXG\'D\DQGUHWXUQIRUDIROORZXSVDIHW\
YLVLWRQ'D\

)DVWLQJ0HDOV%HYHUDJHV

)DVWLQJ0HDOV
3DQHOV	
$QRSWLRQDOPHDORUVQDFNZLOOEHVHUYHGWKHHYHQLQJRIHDFKFKHFNLQ$OOVXEMHFWVZLOO
IDVWIRUDWOHDVWKRXUVDIWHUHDFKGRVH6WDQGDUGPHDOVZLOOEHSURYLGHGDW
DSSUR[LPDWHO\DQGKRXUVDIWHUHDFKGUXJDGPLQLVWUDWLRQDQGDWDSSURSULDWHWLPHV
WKHUHDIWHU0HDOVQDFNPHQXVZLOOEHWKHVDPHIRUDOOVWXG\SHULRGV
6XEMHFWPXVWQRWFRQVXPHEHYHUDJHVDQGIRRGVFRQWDLQLQJDOFRKROJUDSHIUXLWSRSS\
VHHGVEURFFROL%UXVVHOVVSURXWVSRPHJUDQDWHVWDUIUXLWFKDUJULOOHGPHDWRU
FDIIHLQH[DQWKLQHIURPKRXUVEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQXQWLOWKHHQG
RIVWXG\YLVLW6XEMHFWVZLOOEHLQVWUXFWHGQRWWRFRQVXPHDQ\RIWKHDERYHSURGXFWV
KRZHYHUDOORZDQFHIRUDQLVRODWHGVLQJOHLQFLGHQWDOFRQVXPSWLRQPD\EHHYDOXDWHGDQG
DSSURYHGE\WKHVWXG\LQYHVWLJDWRUEDVHGRQWKHSRWHQWLDOIRULQWHUDFWLRQZLWKWKHVWXG\
GUXJ
3DQHOIHG
6XEMHFWVLQ3DQHOZLOOEHUHTXLUHGWRIDVWIRUDWOHDVWKRXUVEHIRUHFRQVXPLQJD
UHTXLUHG)'$VWDQGDUGKLJKIDWKLJKFDORULHEUHDNIDVW6XEMHFWVZLOOUHFHLYHWKH
EUHDNIDVWWREHJLQPLQXWHVEHIRUHVFKHGXOHGDGPLQLVWUDWLRQRIWKHGRVHDQGWRHQG
ODVWELWHWDNHQZLWKLQPLQXWHVEHIRUHGRVLQJ7KHVXEMHFWVZLOOIDVWIRUKRXUV
WKHUHDIWHU7KHIROORZLQJKLJKIDWDSSUR[LPDWHO\RIWRWDOFDORULFFRQWHQWRIWKH
PHDOKLJKFDORULHDSSUR[LPDWHO\FDORULHVEUHDNIDVWZLOOEHLQJHVWHGPLQXWHV
EHIRUHDGPLQLVWUDWLRQRIWKHGUXJ
HJJVIULHGLQEXWWHU
VWULSVRIEDFRQ
VOLFHVRIWRDVWZLWKEXWWHU
RXQFHVRIKDVKEURZQSRWDWRHV
RXQFHVRIZKROHPLON
7KLVPHDOFRQWDLQVDSSUR[LPDWHO\SURWHLQFDORULHVFDUERK\GUDWHFDORULHVDQG
IDWFDORULHV$QHTXLYDOHQWPHDOPD\EHVXEVWLWXWHGZLWKGRFXPHQWDWLRQRIWKH
PHQXDQGFDORULFFRQWHQWV7KHDPRXQWFRQVXPHGE\VXEMHFWVZLOOEHUHFRUGHG
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 23

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
3DQHOIDVWHG
6XEMHFWVLQ3DQHOZLOOEHUHTXLUHGWRIDVWIRUDWOHDVWKRXUVEHIRUHGRVLQJ

%HYHUDJHV
([FHSWIRUWKHURRPWHPSHUDWXUHZDWHUSURYLGHGZLWKWKHVWXG\WUHDWPHQWQRZDWHUPD\
EHFRQVXPHGIRUKRXUEHIRUHHDFKGRVHWKURXJKKRXUDIWHUHDFKGRVH$WRWKHU
WLPHVVXEMHFWVZLOOEHHQFRXUDJHGWRGULQNZDWHUDGOLELWXP

'UXJ$GPLQLVWUDWLRQ
6XEMHFWVZLOOEHDGPLQLVWHUHG7UHDWPHQW$[PJWDEOHWXVLQJWKHLPPHGLDWH
UHOHDVHIRUPXODWLRQZLWKP/RIDPELHQWURRPWHPSHUDWXUHZDWHU6XEMHFWVPXVW
VZDOORZWKHWDEOHWLQWDFWLWVKRXOG127EHFUXVKHGRUFKHZHG
6XEMHFWVZLOOEHDGPLQLVWHUHG7UHDWPHQW%[PJGLVSHUVLEOHWDEOHWVDVIROORZV
FOLQLFVWDIIZLOOGLVSHUVHHDFKWDEOHWLQP/RIDPELHQWURRPWHPSHUDWXUHZDWHU
ZKLFKVXEMHFWVZLOOVZDOORZ)ROORZLQJHDFKP/GRVHFOLQLFVWDIIZLOOWKHQULQVHWKH
VDPHFRQWDLQHUZLWKDQDGGLWLRQDOP/RIDPELHQWURRPWHPSHUDWXUHZKLFKWKH
VXEMHFWVZLOOVZDOORZ6XEMHFWVZLOOWKHQULQVHWKHLUPRXWKVDQGVZDOORZDQDGGLWLRQDO
P/RIDPELHQWURRPWHPSHUDWXUHZDWHU
6XEMHFWVZLOOEHDGPLQLVWHUHG7UHDWPHQW&[PJGLVSHUVLEOHWDEOHWDVIROORZV
FOLQLFVWDIIZLOOGLVSHUVHWKHWDEOHWLQP/RIDPELHQWURRPWHPSHUDWXUHZDWHUZKLFK
VXEMHFWVZLOOVZDOORZ&OLQLFVWDIIZLOOWKHQULQVHWKHVDPHFRQWDLQHUZLWKDQDGGLWLRQDO
P/RIDPELHQWURRPWHPSHUDWXUHZDWHUZKLFKWKHVXEMHFWVZLOOVZDOORZ6XEMHFWV
ZLOOWKHQULQVHWKHLUPRXWKVDQGVZDOORZDQDGGLWLRQDOP/RIDPELHQWURRP
WHPSHUDWXUHZDWHU
6XEMHFWVZLOOEHDGPLQLVWHUHG7UHDWPHQW'[PJGLVSHUVLEOHWDEOHWDVIROORZV
FOLQLFVWDIIZLOOGLVSHUVHWKHWDEOHWLQP/RIDPELHQWURRPWHPSHUDWXUHZDWHUZKLFK
VXEMHFWVZLOOVZDOORZ&OLQLFVWDIIZLOOWKHQULQVHWKHVDPHFRQWDLQHUZLWKDQDGGLWLRQDO
P/RIDPELHQWURRPWHPSHUDWXUHZDWHUZKLFKWKHVXEMHFWVZLOOVZDOORZ6XEMHFWV
ZLOOWKHQULQVHWKHLUPRXWKVDQGVZDOORZDQDGGLWLRQDOP/RIDPELHQWURRP
WHPSHUDWXUHZDWHU
$GGLWLRQDOGHWDLOVZLOOEHSURYLGHGLQDVHSDUDWHPDQXDO
)RUDOOWUHDWPHQWVDPRXWKFKHFNZLOOEHSHUIRUPHGLPPHGLDWHO\DIWHUHDFKGRVHWR
HQVXUHWKDWWKHVWXG\GUXJZDVDSSURSULDWHO\VZDOORZHG$KDQGFKHFNZLOODOVREH
SHUIRUPHGDIWHU7UHDWPHQW$
7KHVXEMHFWVZLOOUHPDLQVHDWHGH[FHSWDVRWKHUZLVHUHTXLUHGIRUVWXG\SURFHGXUHVRU
SHUVRQDOQHHGVIRUWKHILUVWKRXUVDIWHUGRVLQJ6KRXOGWKHQHHGWRPRYHDERXWRFFXU
GXULQJWKHILUVWKRXUVDIWHUHDFKGRVHVXEMHFWVPD\EHHVFRUWHGWRVXFKSURFHGXUHVRU
DFWLYLWLHVE\UHVHDUFKSHUVRQQHODVGHHPHGPHGLFDOO\QHFHVVDU\6XEMHFWVZLOOQRWEH
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 24

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
DOORZHGWROLHGRZQH[FHSWDVGLUHFWHGE\FOLQLFDOVWDIIVHFRQGDU\WR$(VIRUWKHILUVW
 KRXUVDIWHUGRVLQJ

%ORRG6DPSOLQJ3URFHVVLQJDQG6KLSPHQW
%ORRGVDPSOHVIRUDQDO\VLVRI SUHWRPDQLGFRQFHQWUDWLRQVZLOOEH GUDZQ MXVWEHIRUHHDFK
GUXJDGPLQLVWUDWLRQ SUHGRVHDQGDWDQG
 KRXUV DIWHUHDFKGRVH$WRWDORI  P/ [  P/VDPSOHV ZLOO EHFROOHFWHG
IURPHDFKVXEMHFWIRUSKDUPDFRNLQHWLF DQDO\VLV%ORRGVDPSOHV ZLOOEHFROOHFWHGDV
GHWDLOHGLQ$SSHQGL[,3KDUPDFRNLQHWLF6DPSOH&ROOHFWLRQ3URFHVVLQJDQG6KLSPHQW
,QVWUXFWLRQV
x
%ORRGVDPSOHVFROOHFWHGXSWRDQGLQFOXGLQJ KRXUVSRVWGRVHZLWKLQ PLQXWHV
RIVFKHGXOHGWLPHZLOOQRWEHFRQVLGHUHGGHYLDWLRQV
x
%ORRGVDPSOHVFROOHFWHGDIWHU KRXUVSRVWGRVHZLWKLQ  PLQXWHVRIVFKHGXOHG
WLPHZLOOQRWEHFRQVLGHUHGGHYLDWLRQV
7DEOH
$FFHSWDEOH3KDUPDFRNLQHWLF6DPSOLQJ7LPH:LQGRZV
,QYHVWLJDWLRQDQGH[DPLQDWLRQ
$OORZDEOH7LPH:LQGRZ
3RVWGRVH
 KRXUV
!KRXUV
3ODVPDVDPSOHFROOHFWLRQIRU
SKDUPDFRNLQHWLFDVVHVVPHQW 
r  PLQXWHV 
r PLQXWHV 
,QDGGLWLRQDSSUR[LPDWHO\  P/RIEORRGLQWRWDOZLOOEHFROOHFWHG GXULQJWKHVWXG\
IRUWKH FOLQLFDOODERUDWRU\HYDOXDWLRQV DWWKHWLPHSRLQWV VKRZQLQ 7DEOH 7KHWRWDO
YROXPHRIEORRGFROOHFWHGIURPHDFKVXEMHFWLQHDFKWUHDWPHQWVHVVLRQZLOOQRWH[FHHG
DSSUR[LPDWHO\ P/
$GGLWLRQDOEORRGPD\EHFROOHFWHG LIQHFHVVDU\ IRUUHSHDWODERUDWRU\HYDOXDWLRQVRU
$(IROORZXS

(QGRI6WXG\3URFHGXUHV
6XEMHFWVZLOOUHWXUQWRWKH FOLQLFIRUDIROORZXS VDIHW\YLVLWDSSUR[LPDWHO\ GD\VDIWHU
WKHLUILQDOGRVHRIVWXG\PHGLFDWLRQ'XULQJWKLVYLVLWWKH IROORZLQJSURFHGXUHVZLOOEH
FRQGXFWHG
x
%ORRGDQGXULQHZLOOEHFROOHFWHGIRUFOLQLFDOODERUDWRU\WHVWVKHPDWRORJ\
FKHPLVWU\DQGXULQDO\VLV
x
9LWDOVLJQVEORRGSUHVVXUHSXOVHWHPSHUDWXUHUHVSLUDWLRQUDWHDQGSXOVH
R[LPHWU\
x
6LQJOHOHDG(&*
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 25

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
x
3K\VLFDOH[DPLQDWLRQ
x
'UXJ FRWLQLQHDQGDOFRKROWHVWLQJ
x
8ULQHSUHJQDQF\ WHVW DOOIHPDOH VXEMHFWV
x
$Q\XSGDWHVWR$(VDQGRUFRQFRPLWDQW PHGLFDWLRQ
:KHQSRVVLEOHHQGRIVWXG\SURFHGXUHVZLOOEHSHUIRUPHGLQWKHHYHQWRIDVXEMHFW¶V
HDUO\WHUPLQDWLRQIURPWKHVWXG\

6DIHW\0RQLWRULQJDQG3URFHGXUHV

6DIHW\± $GYHUVH(YHQWV
6XEMHFWVZLOOEHLQVWUXFWHGWRLQIRUPWKHVWXG\SK\VLFLDQDQGRUUHVHDUFKSHUVRQQHORI
DQ\$(VWKDWRFFXUDWDQ\WLPHGXULQJWKHVWXG\6XEMHFWV ZLOOEHPRQLWRUHGIRU$(V
IURPWKH VLJQLQJRI WKHLQIRUPHGFRQVHQW WKURXJKWKH IROORZXS YLVLW
5HIHUWR6HFWLRQ  IRUGHWDLOVUHJDUGLQJ$(UHSRUWLQJ

6DIHW\± &OLQLFDO/DERUDWRU\ (YDOXDWLRQV
x &OLQLFDOODERUDWRU\WHVWVKHPDWRORJ\VHUXPFKHPLVWU\ DQGXULQDO\VLVZLOOEH
SHUIRUPHGDWWKHWLPHSRLQWV VKRZQLQWKH(YHQWV6FKHGXOH7DEOH
R
+HPDWRORJ\KHPRJORELQKHPDWRFULWWRWDODQGGLIIHUHQWLDOOHXNRF\WH FRXQWUHG
EORRGFHOOFRXQWDQGSODWHOHWFRXQW
R
6HUXPFKHPLVWU\DOEXPLQEORRGXUHDQLWURJHQFUHDWLQLQHWRWDOELOLUXELQ
DONDOLQHSKRVSKDWDVHDVSDUWDWHWUDQVDPLQDVHDODQLQHWUDQVDPLQDVHVRGLXP
SRWDVVLXPFKORULGHODFWDWHGHK\GURJHQDVHFDOFLXP XULFDFLGJOXFRVHJDPPD
JOXWDP\OWUDQVIHUDVHDQGPDJQHVLXP
R
8ULQDO\VLVS+VSHFLILFJUDYLW\SURWHLQJOXFRVHNHWRQHVELOLUXELQEORRGQLWULWH
OHXNRF\WHHVWHUDVHDQGXURELOLQRJHQ,ISURWHLQRFFXOWEORRGQLWULWHRUOHXNRF\WH
HVWHUDVHYDOXHVDUH RXWRIUDQJHDPLFURVFRSLFH[DPLQDWLRQZLOOEHSHUIRUPHG
x 6HURORJ\  %ORRGZLOOEHWHVWHGIRUKHSDWLWLV % VXUIDFHDQWLJHQKHSDWLWLV &DQWLERG\
DQG+,9 DWVFUHHQLQJ
x 8ULQH'UXJ&RWLQLQHDQG$OFRKRO6FUHHQV  8ULQHVDPSOHVZLOOEHWHVWHGIRUGUXJVRI
DEXVHDPSKHWDPLQHVEHQ]RGLD]HSLQHVEDUELWXUDWHVFDQQDELQRLGVFRFDLQHRSLDWHV
FRWLQLQH DQGDOFRKRO DWVFUHHQLQJDQGFKHFNLQ
x )RUDOOIHPDOHVXEMHFWVD VHUXPSUHJQDQF\WHVWDWVFUHHQLQJDQGFKHFNLQDQGDXULQH
SUHJQDQF\WHVWDWWKHIROORZXSYLVLW
x )ROOLFOHVWLPXODWLQJKRUPRQHSRVWPHQRSDXVDOIHPDOHV DWVFUHHQLQJ
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 26

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
$ &OLQLFDO/DERUDWRU\,PSURYHPHQW$PHQGPHQWV&/,$FHUWLILHGODERUDWRU\ZLOO
SHUIRUPDOOFOLQLFDOODERUDWRU\WHVWVIRUWKLVVWXG\

6DIHW\± 9LWDO6LJQV
9LWDOVLJQVEORRGSUHVVXUHSXOVHUDWHUHVSLUDWLRQUDWHWHPSHUDWXUHDQGSXOVH
R[LPHWU\ZLOOEHPHDVXUHGDWWKHWLPHSRLQWV VKRZQLQWKH(YHQWV6FKHGXOH7DEOH
%RWKEORRGSUHVVXUHDQGKHDUWUDWHSXOVHVKRXOGEHFDSWXUHGVLPXOWDQHRXVO\%ORRG
SUHVVXUHDQG KHDUWUDWHVKRXOGEHPHDVXUHGDIWHUSDUWLFLSDQWVDUHLQDVHDWHGSRVLWLRQIRU
DWOHDVWPLQXWHVDQGWKHQDJDLQDIWHUVWDQGLQJIRU PLQXWHH[FHSWZKHQWKH\DUH
VXSLQHRUVHPLUHFOLQHGEHFDXVHRIVWXG\SURFHGXUHVDQGRUDGYHUVHHYHQWVRUDV
GHHPHGQHFHVVDU\E\WKH,QYHVWLJDWRU
3UHGRVH YLWDOVLJQVZLOOEHDVVHVVHGE\WKH3ULQFLSDO,QYHVWLJDWRURUGHVLJQHHHJD
PHGLFDOO\TXDOLILHG6XE,QYHVWLJDWRUEHIRUH HDFKVWXG\GUXJDGPLQLVWUDWLRQ7KH
3ULQFLSDO,QYHVWLJDWRURUGHVLJQHHZLOOYHULI\WKHHOLJLELOLW\RIHDFKVXEMHFWZLWK
RXWRIUDQJHYLWDOVLJQVDQGGRFXPHQWDSSURYDOEHIRUH GRVLQJ
$GGLWLRQDOYLWDOVLJQVPHDVXUHPHQWVPD\EHSHUIRUPHGDVGHHPHGPHGLFDOO\QHFHVVDU\
E\UHVHDUFKSHUVRQQHO$OOYLWDOVLJQVPHDVXUHPHQWVZLOOEHWDNHQDIWHUWKHVXEMHFWKDV
FRPSOHWHGDPLQLPXPPLQXWHVLW

6DIHW\± 3K\VLFDO([DPLQDWLRQV
$ IXOOSK\VLFDOH[DPLQDWLRQZLOOEHSHUIRUPHGDWVFUHHQLQJ $QDEEUHYLDWHGSK\VLFDO
H[DPLQDWLRQZLOOEHSHUIRUPHGDWFKHFNLQ 'D\ DQGDWHQGRIVWXG\HDUO\
WHUPLQDWLRQ +HLJKWZLOORQO\EHFROOHFWHGDWVFUHHQLQJ

6DIHW\ ± (OHFWURFDUGLRJUDPV
$VLQJOHOHDG(&* ZLOOEHSHUIRUPHGDIWHUWKHVXEMHFWKDVEHHQLQVXSLQHSRVLWLRQ
IRUDPLQLPXPRI PLQXWHV DWVFUHHQLQJDQGRQ6WXG\'D\VDQG7KH\ PXVW
EHSHUIRUPHGZLWKLQ KRXUV SULRUWRGRVLQJDQGFRPSOHWHGPLQXWHV SULRUWRSUHGRVH
EORRGGUDZ (&*VZLOOEHSULQWHGDQGUHYLHZHG RQVLWHE\WKH3ULQFLSDO,QYHVWLJDWRURU
GHVLJQHH

2WKHU6DIHW\0HDVXUHV
0HGLFDOHPHUJHQF\SHUVRQQHO WUDLQHGLQDGYDQFHGFDUGLDFOLIHVXSSRUWZLOOEH RQ VLWHWR
PRQLWRUVXEMHFWVGXULQJWKHFRQILQHPHQWSHULRGLQWKHUHVHDUFKFHQWHU(PHUJHQF\
PHGLFDOHTXLSPHQWLQFOXGLQJEXWQRWOLPLWHGWRLQWXEDWLRQHTXLSPHQWDQGSXOVH
R[LPHWU\VKDOOEHPDLQWDLQHGRQVLWH WRDGPLQLVWHUDSSURSULDWHPHGLFDOFDUHVKRXOGLW EH
UHTXLUHG
3URFHGXUHVZLOOEHFRPSOHWHG DVVSHFLILHGLQWKLVSURWRFROXQOHVVFRQWUDLQGLFDWHGGXHWR
D UHSRUWHG$(
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 27

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH

$'9(56((9(176
7KH,QYHVWLJDWRURUDVXLWDEO\PHGLFDOO\TXDOLILHGGHVLJQHHDUHUHVSRQVLEOHIRUHOLFLWLQJ
DGYHUVHHYHQWVE\REVHUYLQJDQGTXHVWLRQLQJWKHVXEMHFWDQGUHFRUGLQJDOODGYHUVH
HYHQWVREVHUYHGE\KLPKHURUUHSRUWHGE\WKHVXEMHFWGXULQJWKHWULDO

'HILQLWLRQV

$GYHUVH(YHQW
$Q\XQWRZDUGPHGLFDORFFXUUHQFHLQDFOLQLFDOLQYHVWLJDWLRQSDUWLFLSDQWWHPSRUDOO\
DVVRFLDWHGZLWKWKHXVHRIDWULDOWUHDWPHQWZKHWKHURUQRWFRQVLGHUHGUHODWHGWRWULDO
WUHDWPHQW$QDGYHUVHHYHQWFDQWKHUHIRUHEHDQ\XQIDYRUDEOHDQGXQLQWHQGHGVLJQ
LQFOXGLQJDQDEQRUPDOODERUDWRU\ILQGLQJV\PSWRPRUGLVHDVHQHZRUH[DFHUEDWHG
WHPSRUDOO\DVVRFLDWHGZLWKWKHXVHRIDWULDOWUHDWPHQWZKHWKHURUQRWUHODWHGWRWKHWULDO
WUHDWPHQW

6HULRXV$GYHUVH(YHQW
$Q\XQWRZDUGPHGLFDORFFXUUHQFHWKDWDWDQ\GRVH
x 5HVXOWVLQGHDWK
x ,VOLIHWKUHDWHQLQJDQ\HYHQWLQZKLFKWKHSDUWLFLSDQWZDVDWULVNRIGHDWKDWWKHWLPH
RIWKHHYHQWLWGRHVQRWUHIHUWRDQHYHQWZKLFKK\SRWKHWLFDOO\PLJKWKDYHFDXVHG
GHDWKLILWZHUHPRUHVHYHUH
x 5HTXLUHVLQSDWLHQWKRVSLWDOL]DWLRQRUSURORQJDWLRQRIH[LVWLQJKRVSLWDOL]DWLRQ,Q
JHQHUDOKRVSLWDOL]DWLRQVLJQLILHVWKDWWKHSDUWLFLSDQWKDVEHHQGHWDLQHGXVXDOO\
LQYROYLQJDWOHDVWDQRYHUQLJKWVWD\DWWKHKRVSLWDORUHPHUJHQF\ZDUGIRU
REVHUYDWLRQDQGRUWUHDWPHQWWKDWZRXOGQRWKDYHEHHQDSSURSULDWHLQWKH
SK\VLFLDQ¶VRIILFHRURXWSDWLHQWVHWWLQJ&RPSOLFDWLRQVWKDWRFFXUGXULQJ
KRVSLWDOL]DWLRQDUH$(V,IDFRPSOLFDWLRQSURORQJVKRVSLWDOL]DWLRQRUIXOILOOVDQ\
RWKHUVHULRXVFULWHULDWKHHYHQWLVVHULRXV:KHQLQGRXEWDVWRZKHWKHU
³KRVSLWDOL]DWLRQ´RFFXUUHGRUZDVQHFHVVDU\WKH$(VKRXOGEHFRQVLGHUHGVHULRXV
+RVSLWDOL]DWLRQIRUHOHFWLYHWUHDWPHQWRIDSUHH[LVWLQJFRQGLWLRQWKDWGLGQRWZRUVHQ
IURPEDVHOLQHLVQRWFRQVLGHUHGDQ$(
x 5HVXOWVLQSHUVLVWHQWRUVLJQLILFDQWGLVDELOLW\LQFDSDFLW\WKHWHUPGLVDELOLW\PHDQVD
VXEVWDQWLDOGLVUXSWLRQRIDSHUVRQ¶VDELOLW\WRFRQGXFWQRUPDOOLIHIXQFWLRQV7KLV
GHILQLWLRQLVQRWLQWHQGHGWRLQFOXGHH[SHULHQFHVRIUHODWLYHO\PLQRUPHGLFDO
VLJQLILFDQFHVXFKDVXQFRPSOLFDWHGKHDGDFKHQDXVHDYRPLWLQJGLDUUKHDLQIOXHQ]D
DQGDFFLGHQWDOWUDXPDHJVSUDLQHGDQNOHZKLFKPD\LQWHUIHUHZLWKRUSUHYHQW
HYHU\GD\OLIHIXQFWLRQVEXWGRQRWFRQVWLWXWHDVXEVWDQWLDOGLVUXSWLRQ
x ,VDFRQJHQLWDODQRPDO\ELUWKGHIHFWRU
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 28

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
x ,VDPHGLFDOO\LPSRUWDQWHYHQW
1RWH0HGLFDODQGVFLHQWLILFMXGJPHQWVKRXOGEHH[HUFLVHGLQGHFLGLQJZKLFKLVD
PHGLFDOO\LPSRUWDQWHYHQWWKDWPD\QRWEHLPPHGLDWHO\OLIHWKUHDWHQLQJRUUHVXOWLQ
GHDWKRUKRVSLWDOL]DWLRQEXWPD\MHRSDUGL]HWKHSDUWLFLSDQWRUPD\UHTXLUHPHGLFDORU
VXUJLFDOLQWHUYHQWLRQWRSUHYHQWRQHRIWKHRXWFRPHVOLVWHGDERYH([DPSOHVRIVXFK
HYHQWVDUHLQWHQVLYHWUHDWPHQWLQDQHPHUJHQF\URRPRUDWKRPHIRUDOOHUJLF
EURQFKRVSDVPEORRGG\VFUDVLDVRUFRQYXOVLRQVWKDWGRQRWUHVXOWLQKRVSLWDOL]DWLRQRU
WKHGHYHORSPHQWRIGUXJGHSHQGHQF\RUGUXJDEXVH$³VXVSHFWHGWUDQVPLVVLRQRI
LQIHFWLRXVDJHQWE\DPHGLFLQDOSURGXFW´LVDOVRFRQVLGHUHGDVHULRXVDGYHUVHHYHQW
XQGHUWKH6$(FULWHULRQ³2WKHUPHGLFDOO\LPSRUWDQWFRQGLWLRQ´

$WWULEXWLRQ&DXVDOLW\
$QDGYHUVHUHDFWLRQWKHQDWXUHRUVHYHULW\RIZKLFKLVQRWFRQVLVWHQWZLWKWKH
DSSOLFDEOHSURGXFWLQIRUPDWLRQHJ,QYHVWLJDWRU¶V%URFKXUHIRUDQXQDSSURYHG
LQYHVWLJDWLRQDOSURGXFW
x 7KHLQYHVWLJDWRULVREOLJDWHGWRDVVHVVWKHUHODWLRQVKLSEHWZHHQWULDOWUHDWPHQWDQG
HDFKRFFXUUHQFHRIHDFK$(6$(
x 7KHLQYHVWLJDWRUZLOOXVHFOLQLFDOMXGJPHQWWRGHWHUPLQHWKHUHODWLRQVKLS
x $OWHUQDWLYHFDXVHVVXFKDVXQGHUO\LQJGLVHDVHVFRQFRPLWDQWWKHUDS\DQGRWKHU
ULVNIDFWRUVDVZHOODVWKHWHPSRUDOUHODWLRQVKLSRIWKHHYHQWWRWULDOWUHDWPHQW
DGPLQLVWUDWLRQZLOOEHFRQVLGHUHGDQGLQYHVWLJDWHG
x 7KHLQYHVWLJDWRUZLOODOVRFRQVXOWWKH,QYHVWLJDWRU¶V%URFKXUHDQGRU3URGXFW
,QIRUPDWLRQIRUPDUNHWHGSURGXFWVLQKLVKHUDVVHVVPHQW
x )RUHDFK$(6$(WKHLQYHVWLJDWRUPXVWGRFXPHQWLQWKHPHGLFDOQRWHVWKDWKHVKH
KDVUHYLHZHGWKH$(6$(DQGKDVSURYLGHGDQDVVHVVPHQWRIFDXVDOLW\
x 7KHUHPD\EHVLWXDWLRQVLQZKLFKDQ6$(KDVRFFXUUHGDQGWKHLQYHVWLJDWRUKDV
PLQLPDOLQIRUPDWLRQWRLQFOXGHLQWKHLQLWLDOUHSRUWWRWKH6SRQVRUGHVLJQHH
+RZHYHULWLVYHU\LPSRUWDQWWKDWWKHLQYHVWLJDWRUDOZD\VPDNHDQDVVHVVPHQWRI
FDXVDOLW\IRUHYHU\HYHQWEHIRUHWKHLQLWLDOWUDQVPLVVLRQRIWKH6$(GDWDWRWKH
6SRQVRUGHVLJQHH
x 7KHLQYHVWLJDWRUPD\FKDQJHKLVKHURSLQLRQRIFDXVDOLW\LQOLJKWRIIROORZXS
LQIRUPDWLRQDQGVHQGD6$(IROORZXSUHSRUWZLWKWKHXSGDWHGFDXVDOLW\
DVVHVVPHQW
7DEOH
$GYHUVH(YHQW$WWULEXWLRQ&DXVDOLW\5DWLQJV

5HODWHGQHVV5DWLQJ
'HILQLWLRQ
1RW5HODWHG
$QDGYHUVHHYHQWZKLFKLVQRWUHODWHGWRWKHXVHRIWKHGUXJ
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 29

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
5HODWHGQHVV5DWLQJ
'HILQLWLRQ
8QOLNHO\
$QDGYHUVHHYHQWIRUZKLFKDQDOWHUQDWLYHH[SODQDWLRQLVPRUHOLNHO\HJ
FRQFRPLWDQWGUXJVRUFRQFRPLWDQWGLVHDVHVDQGRUWKHUHODWLRQVKLSLQWLPH
VXJJHVWVWKDWDFDXVDOUHODWLRQVKLSLVXQOLNHO\
3RVVLEOH
$QDGYHUVHHYHQWZKLFKPLJKWEHGXHWRWKHXVHRIWKHGUXJ$QDOWHUQDWLYH
H[SODQDWLRQHJFRQFRPLWDQWGUXJVRUFRQFRPLWDQWGLVHDVHVLVLQFRQFOXVLYH
7KHUHODWLRQVKLSLQWLPHLVUHDVRQDEOHWKHUHIRUHWKHFDXVDOUHODWLRQVKLSFDQQRWEH
H[FOXGHG
3UREDEOH
$QDGYHUVHHYHQWZKLFKPLJKWEHGXHWRWKHXVHRIWKHGUXJ7KHUHODWLRQVKLSLQ
WLPHLVVXJJHVWLYHHJFRQILUPHG E\GHFKDOOHQJH$QDOWHUQDWLYHH[SODQDWLRQLV
OHVVOLNHO\HJFRQFRPLWDQWGUXJVRUFRQFRPLWDQWGLVHDVHV
&HUWDLQ
$QDGYHUVHHYHQWZKLFKLVOLVWHGDVDSRVVLEOHDGYHUVHUHDFWLRQDQGFDQQRWEH
UHDVRQDEO\H[SODLQHGE\DQDOWHUQDWLYHH[SODQDWLRQHJFRQFRPLWDQWGUXJVRU
FRQFRPLWDQWGLVHDVHV
7DEOH
'HILQLWLRQVIRU$GYHUVH(YHQW6HYHULW\*UDGLQJV
*UDGH
6HYHULW\5DWLQJ
'HILQLWLRQ
*5$'(
0LOG
7UDQVLHQWRUPLOGGLVFRPIRUWKRXUVQRPHGLFDO
LQWHUYHQWLRQWKHUDS\ UHTXLUHG
*5$'(
0RGHUDWH
0LOGWRPRGHUDWHOLPLWDWLRQLQDFWLYLW\ VRPHDVVLVWDQFHPD\EH
QHHGHGQRRUPLQLPDOPHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHG
*5$'(
6HYHUH
0DUNHGOLPLWDWLRQLQDFWLYLW\VRPHDVVLVWDQFHXVXDOO\UHTXLUHG
PHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHGKRVSLWDOL]DWLRQVSRVVLEOH
*5$'(
3RWHQWLDOO\/LIH
7KUHDWHQLQJ
([WUHPHOLPLWDWLRQLQDFWLYLW\VLJQLILFDQWDVVLVWDQFHUHTXLUHG
VLJQLILFDQWPHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHGKRVSLWDOL]DWLRQRU
KRVSLFHFDUHSUREDEOH
6HH$SSHQGL[  IRUIXOO'0,'7R[LFLW\7DEOHV7KHDERYHUDWLQJVVKRXOGEHXVHGWR
HVWLPDWHWKHJUDGHIRUDEQRUPDOLWLHV127IRXQGHOVHZKHUHLQWKH7R[LFLW\7DEOHV /DE
UHVXOWVZLWKLQWKHWHVWLQJIDFLOLW\¶VQRUPDOUDQJH ZLOOQRWEHFRQVLGHUHG$(VZKHQ
UHIHUHQFHGWRWKH '0,'DVVHVVPHQWJUDGLQJVFDOH$SSHQGL[
/DERUDWRU\DEQRUPDOLWLHVDQGFDUGLRYDVFXODUILQGLQJVRIK\SHUWHQVLRQRU K\SRWHQVLRQ
*UDGHRUDERYHRQWKH'0,'WR[LFLW\WDEOHVZLOOEHFRQVLGHUHG$(V

5HSRUWLQJ

$GYHUVH(YHQW
$GYHUVH(YHQWVZLOOEHFROOHFWHGE\ WKH,QYHVWLJDWRURUTXDOLILHGGHVLJQHHVIURPWKH
WLPHDVXEMHFWVLJQVWKH,QIRUPHG&RQVHQW)RUPWKURXJKWKHIROORZXS SKRQHFDOOV
'D\GD\ $Q\$(VHULRXVRUQRQVHULRXVREVHUYHGE\WKH,QYHVWLJDWRURUD
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 30

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
VXLWDEO\PHGLFDOO\TXDOLILHGGHVLJQHHRUUHSRUWHGE\WKHVXEMHFWZLOOEHUHFRUGHGRQWKH
$GYHUVH(YHQW&DVH5HSRUW)RUP7KH,QYHVWLJDWRUZLOOUHYLHZHDFK$(DQGDVVHVVLWV
UHODWLRQVKLSWRGUXJWUHDWPHQWEDVHGRQDOODYDLODEOHLQIRUPDWLRQDWWKHWLPHRIWKH
FRPSOHWLRQRIWKH&5)7KHIROORZLQJLQIRUPDWLRQZLOOEHUHFRUGHGIRUHDFK$GYHUVH
(YHQWUHSRUWHG
x 'LDJQRVLVRIWKH$(LISRVVLEOH,QWKHFDVHZKHUHDQRYHUDOOGLDJQRVLVFDQQRWEH
PDGHHDFKVSHFLILFVLJQDQGRUV\PSWRPZLOOEHUHFRUGHGDVLQGLYLGXDO$(V
x 'DWHRIRQVHW
x 6WRSGDWHZLWKGXUDWLRQLIDSSOLFDEOH
x 6HYHULW\
x $FWLRQWDNHQZLWK,03
x 2WKHUDFWLRQWDNHQ
x 2XWFRPH
x 5HODWLRQVKLSWR,03
x 2FFXUUHQFH
x 6HULRXVQHVV

6HULRXV$GYHUVH(YHQW5HSRUWLQJ
7KH,QYHVWLJDWRURUGHVLJQHHZLOOQRWLI\WKHDSSURSULDWH6SRQVRUFRQWDFWLPPHGLDWHO\
DIWHUWKH6$(GHWHFWLRQREVHUYDWLRQRUUHSRUWRIRFFXUUHQFHUHJDUGOHVVRIWKH
UHODWLRQVKLSWRWHVWDUWLFOH7KH6SRQVRUFRQWDFWLQIRUPDWLRQIRU6$(UHSRUWLQJLV
SURYLGHGEHORZ
33'39*SKDUPDFRYLJLODQFHVHUYLFHSURYLGHUIRU7%$OOLDQFH
(PDLOUWSVDIHW\#SSGLFRP
6DIHW\+RWOLQH
6DIHW\)D[1XPEHU
$QG
$QWRQLR7RQ\/RPEDUGL0'
*OREDO$OOLDQFHIRU7%'UXJ'HYHORSPHQW
:DOO6WUHHWWK)ORRU
1HZ<RUN1<8QLWHG6WDWHVRI$PHULFD
7HOHSKRQH
0RELOH
)DFVLPLOH
(PDLO$QWRQLR/RPEDUGL&RQVXOWDQW#WEDOOLDQFHRUJ
7KHVH6$(UHSRUWVPXVWFRQWDLQWKHIROORZLQJLQIRUPDWLRQ
$ 6WXG\QDPHQXPEHUIRU(8DOVRWKH(XGUDFWQXPEHU
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 31

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
% 6WXG\GUXJ
& ,QYHVWLJDWRUGHWDLOVQDPHSKRQHID[HPDLO
' 6XEMHFWQXPEHU
( 6XEMHFWGHPRJUDSKLFV
) &OLQLFDOHYHQW
 'HVFULSWLRQ
 'DWHRIRQVHW
 7UHDWPHQWGUXJGRVHGRVDJHIRUP
 $GYHUVHHYHQWUHODWLRQVKLSWRVWXG\GUXJ
 $FWLRQWDNHQUHJDUGLQJVWXG\GUXJLQGLUHFWUHODWLRQVKLSWRWKH$(
* ,IWKH$(ZDVIDWDORUOLIHWKUHDWHQLQJ
+ ,IDSSOLFDEOHFDXVHRIGHDWKZKHWKHURUQRWWKHGHDWKZDVUHODWHGWRVWXG\GUXJ
, ,IDSSOLFDEOHDXWRSV\ILQGLQJVLIDYDLODEOH
$Q\QHZ6$(WKDWRFFXUVZLWKLQRQHPRQWKDIWHUWKHVWXG\SHULRGDQGLVFRQVLGHUHGWR
EHSRVVLEO\UHODWHGWRWKH,QYHVWLJDWLRQDO3URGXFW,3VKRXOGEHUHFRUGHGDQGUHSRUWHG
LPPHGLDWHO\WRWKH6SRQVRU
7KHSHUVRQUHVSRQVLEOHIRUWKHVWXG\VKDOOWDNHFDUHWKDWWKHVWXG\KDVEHHQFDUULHGRXW
LQDFFRUGDQFHZLWKSKDUPDFRYLJLODQFHORFDOUHJXODWLRQV
$OOVHULRXVHYHQWUHSRUWLQJZLOODGKHUHWR86&RGHRI)HGHUDO5HJXODWLRQV
&)53DUWIRU,1'GUXJVDQG&)5IRUPDUNHWHGGUXJVGD\
DOHUWV7KH,QVWLWXWLRQDO5HYLHZ%RDUG,5%ZLOOEHQRWLILHGRIWKHDOHUWUHSRUWVSHU
)RRGDQG'UXJ$GPLQLVWUDWLRQ)'$UHJXODWLRQV
$OO$(VLQFOXGLQJ6$(VZLOOEHIROORZHGWRUHVROXWLRQZKHQSRVVLEOH$OO$(VDQG
WUHDWPHQWDGPLQLVWHUHGZLOOEHUHFRUGHGRQWKHFDVHUHSRUWIRUP&5)
7KH6SRQVRUZLOOEHUHVSRQVLEOHIRUSURFHVVLQJDQGUHSRUWLQJDQ\6$(VDQGWKHLU
UHOHYDQWXSGDWHVWRWKH)'$RURWKHUDSSOLFDEOHUHJXODWRU\DJHQF\

)ROORZXSRI$GYHUVH(YHQWV
$OO$(VZLOOEHIROORZHGXQWLO
x 6DWLVIDFWRU\FOLQLFDOUHVROXWLRQRUVWDELOL]DWLRQRU
x (QGRIWKHIROORZXSSHULRGDQG
x $OOTXHULHVRQWKHVH$(VKDYHEHHQUHVROYHG
&HUWDLQORQJWHUP$(VFDQQRWEHIROORZHGXQWLOUHVROXWLRQZLWKLQWKHVHWWLQJRIWKLV
SURWRFRO,QWKHVHFDVHVIROORZXSZLOOEHWKHUHVSRQVLELOLW\RIWKHWUHDWLQJSK\VLFLDQ
+RZHYHUWKLVZLOOKDYHWREHDJUHHGXSRQZLWKWKH6SRQVRU0HGLFDO0RQLWRU
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 32

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
7KHLQYHVWLJDWRULVREOLJDWHGWRSHUIRUPRUDUUDQJHIRUWKHFRQGXFWRIVXSSOHPHQWDO
PHDVXUHPHQWVDQGRUHYDOXDWLRQVDVPHGLFDOO\LQGLFDWHGRUDVUHTXHVWHGE\6SRQVRURU
UHSUHVHQWDWLYHWRHOXFLGDWHWKHQDWXUHDQGRUFDXVDOLW\RIWKH$(RU6$(DVIXOO\DV
SRVVLEOH7KLVPD\LQFOXGHDGGLWLRQDOODERUDWRU\WHVWVRULQYHVWLJDWLRQV
KLVWRSDWKRORJLFDOH[DPLQDWLRQVRUFRQVXOWDWLRQZLWKRWKHUKHDOWKFDUHSURIHVVLRQDOV
,QYHVWLJDWRUVKRXOGFRQWDFWVSRQVRUGHVLJQHHWRGLVFXVVDSSURSULDWHPHGLFDOIROORZXS
LIFRQVXOWDWLRQUHTXLUHG
,IDSDUWLFLSDQWGLHVGXULQJSDUWLFLSDWLRQLQWKHWULDORUGXULQJDUHFRJQL]HGIROORZXS
SHULRGWKHLQYHVWLJDWRUZLOOSURYLGHVSRQVRUUHSUHVHQWDWLYHZLWKDFRS\RIDQ\SRVW
PRUWHPILQGLQJVLQFOXGLQJKLVWRSDWKRORJ\
1HZRUXSGDWHGLQIRUPDWLRQRQDQ6$(ZLOOEHUHFRUGHGLQWKHRULJLQDOO\FRPSOHWHG
&5)DQGVXEPLWWHGWRVSRQVRUZLWKLQKRXUVRIWKHLQIRUPDWLRQEHFRPLQJNQRZQSHU
6$(UHSRUWLQJJXLGHOLQHV

3RVW7ULDO6HULRXV$GYHUVH(YHQWV
$Q\QHZ6$(VUHSRUWHGE\WKHVXEMHFWWRWKH,QYHVWLJDWRUWKDWRFFXUXSWRGD\VDIWHU
ODVWFRQWDFWDQGDUHGHWHUPLQHGE\WKH3ULQFLSDO,QYHVWLJDWRUWREHSRVVLEOHSUREDEOHRU
YHU\OLNHO\UHODWHGWRWKHXVHRIWKH,03ZLOOEHUHSRUWHGWRWKH6SRQVRU,5%DQG)'$
RQ DQ H[SHGLWHG EDVLV DV UHTXLUHG LQ DFFRUGDQFH ZLWK ORFDO UHTXLUHPHQWV DQG ,&+
JXLGHOLQHVIRU*&3

&OLQLFDO/DERUDWRU\$GYHUVH(YHQWV
&KDQJHVLQWKHUHVXOWVRIWKH&OLQLFDO/DERUDWRU\DVVHVVPHQWUHVXOWVZKLFKWKH
,QYHVWLJDWRUIHHOVDUHFOLQLFDOO\VLJQLILFDQWZLOOEHUHSRUWHGDVDGYHUVHHYHQWV,WLVWKH
,QYHVWLJDWRUV¶UHVSRQVLELOLW\WRUHYLHZWKHUHVXOWVRIDOOODERUDWRU\WHVWVDVWKH\EHFRPH
DYDLODEOH7KLVUHYLHZPXVWEHGRFXPHQWHGE\WKH,QYHVWLJDWRUV¶GDWHGVLJQDWXUHRQWKH
ODERUDWRU\UHSRUW)RUHDFKDEQRUPDOODERUDWRU\WHVWUHVXOWWKH,QYHVWLJDWRUQHHGVWR
DVFHUWDLQDQGGRFXPHQWLIWKLVLVDFOLQLFDOO\VLJQLILFDQWFKDQJHIURPEDVHOLQHIRUWKDW
LQGLYLGXDOSDUWLFLSDQW7KLVGHWHUPLQDWLRQKRZHYHUGRHVQRWQHFHVVDULO\QHHGWREH
PDGHWKHILUVWWLPHDQDEQRUPDOYDOXHLVREVHUYHG7KH,QYHVWLJDWRUPD\UHSHDWWKH
ODERUDWRU\WHVWRUUHTXHVWDGGLWLRQDOWHVWVWRYHULI\WKHUHVXOWVRIWKHRULJLQDOODERUDWRU\
WHVWV,IWKLVODERUDWRU\YDOXHLVGHWHUPLQHGE\WKH,QYHVWLJDWRUWREHDFOLQLFDOO\
VLJQLILFDQWFKDQJHIURPEDVHOLQHIRUWKDWSDUWLFLSDQWLWLVFRQVLGHUHGWREHDQDGYHUVH
HYHQW

'UXJ,QWHUDFWLRQ
,IWKH,QYHVWLJDWRUEHFRPHVDZDUHWKDWWKHVXEMHFWKDVH[SHULHQFHGDGUXJLQWHUDFWLRQ
ZKLFKKDVUHVXOWHGLQDQDGYHUVHHYHQWLWZLOOEHUHFRUGHGDVDQDGYHUVHHYHQW
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 33

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH

3UHJQDQF\
7KH,QYHVWLJDWRUZLOOLPPHGLDWHO\QRWLI\WKH6SRQVRURIDQ\SUHJQDQF\WKDWLV
GLVFRYHUHGGXULQJWKHFOLQLFDOWULDO3UHJQDQF\IRUPVZLOOEHFRPSOHWHGIRUDOO
SUHJQDQFLHVUHSRUWHGGXULQJWKHVWXG\RULQWKHGD\VDIWHUFRPSOHWLRQRIWKH,03,Q
DGGLWLRQWKH,QYHVWLJDWRUZLOOUHSRUWWRWKH6SRQVRUIROORZXSLQIRUPDWLRQUHJDUGLQJWKH
RXWFRPHRIWKHSUHJQDQF\LQFOXGLQJSHULQDWDODQGQHRQDWDORXWFRPH,QIDQWVVKRXOGEH
IROORZHGIRUPRQWKV
,ISUHJQDQF\LVVXVSHFWHGZKLOHWKHVXEMHFWLVUHFHLYLQJ,03WKH,03ZLOOEHZLWKKHOG
LPPHGLDWHO\XQWLOWKHUHVXOWRIWKHSUHJQDQF\WHVWLVNQRZQ,ISUHJQDQF\LVFRQILUPHG
WKH,03ZLOOEHSHUPDQHQWO\GLVFRQWLQXHGLQDQDSSURSULDWHPDQQHUDQGWKHVXEMHFW
ZLWKGUDZQIURPWKHWULDO3URWRFROUHTXLUHGSURFHGXUHVIRUWULDOGLVFRQWLQXDWLRQDQG
IROORZXSZLOOEHSHUIRUPHGXQOHVVFRQWUDLQGLFDWHGE\WKHSUHJQDQF\
,IWKH,QYHVWLJDWRUEHFRPHVDZDUHWKHIHPDOHSDUWQHURIDPDOHVXEMHFWEHFRPHV
SUHJQDQWGXULQJWKHVWXG\RULQWKHGD\VDIWHUWKHFRPSOHWLRQRI,03FRQVHQWZLOOEH
UHTXHVWHGIURPWKHIHPDOHSDUWQHUIRUFROOHFWLRQRILQIRUPDWLRQRQKHUSUHJQDQF\
KLVWRU\DQGIRULQIRUPDWLRQRQWKHFXUUHQWSUHJQDQF\DQGELUWK

*(1(5$/&216,'(5$7,216

%DVLF3ULQFLSOHV
7KLVUHVHDUFKZLOOEHFDUULHGRXWLQDFFRUGDQFHZLWKWKHSURWRFROWKH,QWHUQDWLRQDO
&RXQFLOIRU+DUPRQLVDWLRQ,&+*XLGHOLQHIRU*RRG&OLQLFDO3UDFWLFH&RQVROLGDWHG
*XLGDQFH(DQGDSSOLFDEOHUHJXODWRU\UHTXLUHPHQWVVLQFOXGLQJFOLQLFDOUHVHDUFK
JXLGHOLQHVHVWDEOLVKHGE\WKH%DVLF3ULQFLSOHVGHILQHGLQWKH86&)53DUWV
DQGDQGWKHSULQFLSOHVHQXQFLDWHGLQWKH'HFODUDWLRQRI+HOVLQNLUHYLVHGYHUVLRQ
)RUWDOH]D

,QVWLWXWLRQDO5HYLHZ%RDUG
7KLVSURWRFROZLOOEHUHYLHZHGE\DQDSSURSULDWH,5%DQGVWXG\HQUROOPHQWZLOOQRW
FRPPHQFHXQWLOWKH%RDUGKDVDSSURYHGWKHSURWRFRORUDPRGLILFDWLRQWKHUHRI7KH
%RDUGLVFRQVWLWXWHGDQGRSHUDWHVLQDFFRUGDQFHZLWKWKHSULQFLSOHVDQGUHTXLUHPHQWV
GHVFULEHGLQ&)53DUW

,QIRUPHG&RQVHQW
:ULWWHQLQIRUPHGFRQVHQWZLOOEHREWDLQHGIURPHDFKVXEMHFWEHIRUHSHUIRUPLQJDQ\
EDVHOLQHVWXG\VSHFLILFHYDOXDWLRQV7KHLQIRUPHGFRQVHQWGRFXPHQWLVSUHSDUHGE\WKH
,QYHVWLJDWRURUGHVLJQHHVXEMHFWWRUHYLHZDQGDSSURYDOE\WKH6SRQVRUDQGIRUZDUGHG
WRDTXDOLILHG,5%IRUILQDOUHYLHZDQGDSSURYDO7KH,5%DSSURYHGGRFXPHQWPXVW
FRQWDLQDWPLQLPXPWKHHLJKWEDVLFHOHPHQWVRILQIRUPHGFRQVHQW2QO\WKHPRVW
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 34

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
UHFHQWO\,5%DSSURYHG,QIRUPHG&RQVHQW'RFXPHQWPXVWEHXVHGWRFRQVHQW
SURVSHFWLYHVWXG\VXEMHFWV2QHFRS\RIWKHVLJQHGDQGGDWHGLQIRUPHGFRQVHQW
GRFXPHQWZLOOEHJLYHQWRWKHVXEMHFWDQGWKHRULJLQDOUHWDLQHGE\ WKH ,QYHVWLJDWRUVLWH

,QGLFDWLRQVIRU6XEMHFW:LWKGUDZDO
6XEMHFWV ZLOOEHIUHHWRZLWKGUDZDWDQ\WLPHIRUDQ\UHDVRQRUWKH\PD\EHZLWKGUDZQ
LIQHFHVVDU\WRSURWHFWWKHLUKHDOWKDQGVDIHW\RUWKHLQWHJULW\RIWKHVWXG\GDWD
6XEMHFWVZKRDUHZLWKGUDZQIURPWKHVWXG\ZLOOQRW EHUHSODFHG 6XEMHFWVLQ3DQHO
IHGZKRGRQRWFRPSOHWHWKHUHTXLUHG)'$VWDQGDUGKLJKIDWKLJKFDORULHEUHDNIDVW
ZLOOEHZLWKGUDZQIURPWKDWVWXG\SHULRG
7KHILQDOUHSRUWZLOOLQFOXGHUHDVRQVIRUZLWKGUDZDOV,QWKHHYHQWRIDQHDUO\
WHUPLQDWLRQVXEMHFWVZLOOXQGHUJRWKHSURFHGXUHVGHVFULEHGLQ 6HFWLRQ

7HUPLQDWLRQRIWKH 6WXG\
7KH3ULQFLSDO,QYHVWLJDWRUUHVHUYHVWKHULJKWWRWHUPLQDWHWKHVWXG\ LQWKHLQWHUHVWRI
VXEMHFWVDIHW\DQGZHOIDUH7KH6SRQVRU UHVHUYHVWKHULJKWWRWHUPLQDWHWKHVWXG\DWDQ\
WLPHIRUDGPLQLVWUDWLYHUHDVRQV

'RFXPHQWDWLRQ
$OOGRFXPHQWVSHUWDLQLQJWRWKHVWXG\LQFOXGLQJDFRS\RIWKHDSSURYHGSURWRFROFRS\
RIWKHLQIRUPHGFRQVHQWGRFXPHQWDQG+HDOWK ,QVXUDQFH3RUWDELOLW\DQG$FFRXQWDELOLW\
$FW+,3$$GRFXPHQWVFRPSOHWHG&5)VZKHUHDSSOLFDEOHGUXJDFFRXQWDELOLW\DQG
UHWHQWLRQUHFRUGVDQGRWKHUVWXG\UHODWHGGRFXPHQWVZLOOEHUHWDLQHGLQ WKHSHUPDQHQW
DUFKLYHVRIWKH VWXG\VLWH7KHVHZLOOEHDYDLODEOHIRULQVSHFWLRQDWDQ\WLPHE\WKH
6SRQVRURUWKH)'$3HU &)5 UHFRUGUHWHQWLRQIRUWKLVVWXG\LVUHTXLUHGIRUD
SHULRGRIWZR\HDUVIROORZLQJWKHGDWHRQZKLFKWKLVVWXG\DJHQWLVDSSURYHGE\WKH
)'$IRUWKHPDUNHWLQJSXUSRVHVWKDWZHUHWKHVXEMHFWRIWKLVLQYHVWLJDWLRQRULIQR
DSSOLFDWLRQLVWREHILOHGRULIWKHDSSOLFDWLRQLVQRWDSSURYHGIRUVXFKLQGLFDWLRQXQWLO
WZR\HDUVIROORZLQJWKHGDWHRQZKLFKWKHHQWLUHVWXG\ LVFRPSOHWHGWHUPLQDWHGRU
GLVFRQWLQXHGDQGWKH)'$LVQRWLILHG
6XEMHFWUHFRUGVZLOOEH NHSWSULYDWHH[FHSWZKHQRUGHUHGE\ODZ7KHIROORZLQJ
LQGLYLGXDOVZLOOKDYHDFFHVVWRVWXG\VXEMHFWUHFRUGV3ULQFLSDO,QYHVWLJDWRUDQG
GHVLJQHHVVWXG\6SRQVRUPRQLWRUV DQGDXGLWRUVWKH)'$RWKHUJRYHUQPHQWRIILFHV
DQGWKH,5%

7ULDO0RQLWRULQJ
6SRQVRUSHUVRQQHORUGHVLJQHHVZLOOEHUHVSRQVLEOHIRUPRQLWRULQJWKHVWXG\WRHQVXUH
FRPSOLDQFHZLWKWKHSURWRFRODQG*&3&RPSOLDQFHPD\EHYHULILHGE\RQHRUPRUHRI
WKHIROORZLQJPHWKRGVRQVLWHYLVLWVIUHTXHQWFRPPXQLFDWLRQZLWK WKH,QYHVWLJDWRU
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 35

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
DQGRUUHYLHZRI&5)VDQGVRXUFHGRFXPHQWV7KH,QYHVWLJDWRUDJUHHVWRSHUPLWVXFK
PRQLWRULQJDVZHOODVDXGLWVRUUHYLHZVE\UHJXODWRU\DXWKRULWLHVDQGWKH,5%

5HLPEXUVHPHQW,QGHPQLW\DQG,QVXUDQFH
5HLPEXUVHPHQWLQGHPQLW\DQGLQVXUDQFHVKDOOEHDGGUHVVHGLQDVHSDUDWHDJUHHPHQW
RQWHUPVDJUHHGXSRQE\WKHSDUWLHV

3+$50$&2.,1(7,&$1$/<6,6

$QDO\WLFDO0HWKRGRORJ\
3ODVPDVDPSOHVZLOOEHDQDO\]HGIRUSUHWRPDQLGXVLQJDYDOLGDWHGDVVD\7KHVDPSOHV
IURPDOOHYDOXDEOHVXEMHFWVFRPSOHWLQJDWOHDVWRQHVWXG\SHULRGZLOOEHDQDO\]HG
6DPSOHVIURPVXEMHFWVZKRH[SHULHQFHHPHVLVZLWKLQKRXUVRIGRVLQJZLOOQRWEH
DQDO\]HG

3KDUPDFRNLQHWLFDQG6WDWLVWLFDO$QDO\VHV
3ULPDU\SKDUPDFRNLQHWLFPHDVXUHVLQFOXGH7PD[&PD[$8&WDQG$8&LQI
6HFRQGDU\SKDUPDFRNLQHWLFPHDVXUHVLQFOXGHWKHUDWLRRI$8&WWR$8&LQI7.HO
&O)DQG9G)
$OOHYDOXDEOHVXEMHFWVFRPSOHWLQJDWOHDVWRQHWUHDWPHQWSHULRGZLOOEHLQFOXGHGLQWKH
SKDUPDFRNLQHWLFDQDO\VLV
'HVFULSWLYHVWDWLVWLFVZLOOEHXVHGWRVXPPDUL]HSUHWRPDQLGSODVPDFRQFHQWUDWLRQVDW
HDFKVDPSOLQJWLPHSRLQWDQGIRUGHULYHGSODVPD3.SDUDPHWHUVDVDSSOLFDEOH
6WDWLVWLFVLQFOXGHVDPSOHVL]HQPHDQ6'SHUFHQWDJHFRHIILFLHQWRIYDULDWLRQ&9
JHRPHWULFPHDQPHGLDQPLQLPXPDQGPD[LPXP
)RUHDFKSDUWLFLSDQWSUHWRPDQLGSODVPDFRQFHQWUDWLRQWLPHGDWDZLOOEHJUDSKLFDOO\
SUHVHQWHG6LPLODUO\JUDSKVRIWKHPHDQSODVPDFRQFHQWUDWLRQWLPHSURILOHVDQG
RYHUOD\JUDSKVZLWKFRPELQHGLQGLYLGXDOSODVPDFRQFHQWUDWLRQWLPHSURILOHVZLOOEH
SURGXFHG$GGLWLRQDOO\SKDUPDFRNLQHWLFSDUDPHWHUVPD\EHH[SORUHGJUDSKLFDOO\
7KHELRDYDLODELOLW\RI[PJGLVSHUVLEOHWDEOHWVUHODWLYHWRWKHPJUHIHUHQFH
WDEOHWZLOOEHGHWHUPLQHGVHSDUDWHO\IRUHDFKSDQHOXVLQJDPL[HGPRGHOZLWKWKHORJ
WUDQVIRUPHG3.SDUDPHWHU&PD[$8&WDQG$8&LQIDVUHVSRQVHYDULDEOHVHTXHQFH
SHULRGDQGWUHDWPHQWDVIL[HGHIIHFWVDQGSDUWLFLSDQWDVUDQGRPHIIHFW
7KHHIIHFWRIGRVHRQWKHUHODWLYHELRDYDLODELOLW\RIWKHGLVSHUVLEOHWDEOHWZLOOEH
GHWHUPLQHGVHSDUDWHO\IRUHDFKSDQHOXVLQJWKHVDPHPRGHODVDERYH
7KHHIIHFWRIIRRGRQWKHUHODWLYHELRDYDLODELOLW\RISUHWRPDQLGZLOOEHGHWHUPLQHG
FRPSDULQJDFURVVSDQHOVHDFKIRUPXODWLRQDQGGRVHWDNHQDIWHUHDWLQJEUHDNIDVWYHUVXV
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 36

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
WKHVDPHIRUPXODWLRQDQGGRVHWDNHQLQIDVWHGFRQGLWLRQVXVLQJDPL[HGPRGHOZLWKWKH
ORJWUDQVIRUPHG3.SDUDPHWHUDVUHVSRQVHYDULDEOHSDQHOVHTXHQFHSHULRGWUHDWPHQW
DQGSDQHOE\WUHDWPHQWLQWHUDFWLRQDVIL[HGHIIHFWVDQGSDUWLFLSDQWDVUDQGRPHIIHFW
7KH7PD[RISUHWRPDQLGIRUHDFKRIWKHIRUPXODWLRQVZLOOEHGHVFULSWLYHO\FRPSDUHG
2WKHUVWDWLVWLFDOPRGHOVDQGRUSRSXODWLRQSKDUPDFRNLQHWLFPRGHOOLQJPD\DOVREHXVHG
IRUIXUWKHUGDWDLQWHUSUHWDWLRQ
3KDUPDFRNLQHWLFFDOFXODWLRQVZLOOEHSHUIRUPHGXVLQJDSSURSULDWHVRIWZDUH

)$&,/,7,(6
&/,1,&$/75,$/6,7(
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&
1(/RRS6XLWH
6DQ$QWRQLR7H[DV
7HOHSKRQH
)D[

&/,1,&$//$%25$725,(6
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&
1(/RRS6XLWH
6DQ$QWRQLR7H[DV
7HOHSKRQH
)D[

$1$/<7,&$//$%25$725<
$OOLDQFH3KDUPD,QF
3URMHFW0DQDJHU0LFKHOOH%ODFN
&RQWDFWIRU6DPSOH6KLSPHQW$QQD&XFLQRWWD
/HH%RXOHYDUG
0DOYHUQ3$
3KRQH
)D[
(PDLOVDPSOHV#DOOLDQFHSKDUPDFRFRP
:HEZZZDOOLDQFHSKDUPDFRFRP
&/,1,&$/021,725
0LFKHOOH%HKQNH&&5$
6U&OLQLFDO5HVHDUFK$VVRFLDWH&RQVXOWDQW7%$OOLDQFH
3KRQH
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 37

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
(PDLOPLFKHOOHEHKQNHFRQVXOWDQW#WEDOOLDQFHRUJ
'$7$0$1$*(0(17$1'67$7,67,&6
:RUOGZLGH&OLQLFDO7ULDOV/WG
VW)ORRU:DWHUIURQW+RXVH
%HHVWRQ%XVLQHVV3DUN
%HHVWRQ1RWWLQJKDP
1*/$8.
7HOHSKRQH
)D[

'58*6833/,(6
7%$OOLDQFHZLOOVXSSO\VXIILFLHQWTXDQWLWLHVRIDOOVWXG\GUXJIRUPXODWLRQVWRDOORZ
FRPSOHWLRQRIWKLVVWXG\
6WXG\GUXJIRUPXODWLRQVZLOOEHVKLSSHGWR:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH
6HUYLFHV//&SXUVXDQWWRVLWHVWDQGDUGRSHUDWLQJSURFHGXUHV8SRQUHFHLSWRIWKHVWXG\
GUXJSURGXFWVWKHVXSSOLHVZLOOEHLQYHQWRULHGDQGVWRUHGLQDQHQYLURQPHQWDOO\
FRQWUROOHGDQGVHFXUHOLPLWHGDFFHVVDUHD7KHORWQXPEHUVRIWKHGUXJVDORQJZLWKWKH
H[SLUDWLRQGDWHVZKHUHDYDLODEOHZLOOEHUHFRUGHGDQGFRSLHVRIWKH&HUWLILFDWHRI
$QDO\VLVZKHUHDYDLODEOHZLOOEHPDLQWDLQHGRQILOH5HFRUGVZLOOEHPDLQWDLQHGRI
WKHUHFHLSWDQGGLVSHQVDWLRQRIWKHGUXJVVXSSOLHG
6XIILFLHQWTXDQWLWLHVRIVWXG\GUXJZLOOEHVXSSOLHGWRDOORZIRUUHWHQWLRQVDPSOHV
5HWHQWLRQVDPSOHVZLOOEHVWRUHGDWWKHFOLQLFDOVLWHSXUVXDQWWRWKHVLWH623V7KHVLWH
ZLOOEHUHVSRQVLEOHIRUUDQGRPO\VHOHFWLQJGRVHVWREHDGPLQLVWHUHGDQGGRVHVWREH
UHWDLQHG$WWKHFRQFOXVLRQRIWKHVWXG\DQ\XQXVHGVWXG\GUXJQRWLQFOXGLQJUHWHQWLRQ
VDPSOHVZLOOEHUHWXUQHGWRWKHVSRQVRURUGHVWUR\HGE\WKHVLWHSXUVXDQWWRZULWWHQ
DXWKRUL]DWLRQE\WKHVSRQVRUDQGDSSOLFDEOHIHGHUDODQGVWDWHUHJXODWLRQV

$'0,1,675$7,9(,668(6
7KH,QYHVWLJDWRULVUHIHUUHGWRWKH,QYHVWLJDWRU%URFKXUHIRUSUHWRPDQLG3$
LQIRUPDWLRQSURYLGHGGXULQJWKHVWXG\LQLWLDWLRQYLVLWDQG,&+*XLGHOLQHVIRU*RRG
&OLQLFDO3UDFWLFHIRULQIRUPDWLRQUHJDUGLQJWKHVWXG\GUXJGHWDLOVRUJHQHUDO
FRQVLGHUDWLRQVWREHIROORZHGGXULQJWKHFRXUVHRIWKLVVWXG\
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 38

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH

(9(1766&+('8/(
7DEOH
6FKHGXOHRI$VVHVVPHQWVDQG3URFHGXUHV

6&5
&RQILQHPHQW7R'D\
678'<3(5,2'

WR

6HVVLRQ
%UHDN
6HVVLRQ
%UHDN
6HVVLRQ
%UHDN
6HVVLRQ
678'<'$<









               RUHDUO\
ZLWKGUDZDO
:ULWWHQLQIRUPHGFRQVHQW
DQGPHGLFDOKLVWRU\
;

























8SGDWHGPHGLFDOKLVWRU\

;
























+HLJKW
;

























:HLJKW
;
;
























3K\VLFDOH[DPLQDWLRQD
;
;























;
9LWDOVLJQVEORRGSUHVVXUHSXOVH
WHPSHUDWXUHUHVSLUDWLRQUDWHDQG
SXOVHR[LPHWU\E

;
;
;
;
;
; ;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
6LQJOHOHDG(&*F
;
;
;





;





;





;




;
+,9KHSDWLWLV%VXUIDFHDQWLJHQ
DQGKHSDWLWLV&
;

























&OLQLFDOODERUDWRU\WHVWV
KHPDWRORJ\FKHPLVWU\DQG
XULQDO\VLVG

;
;




;





;





;





;

;
8ULQHGUXJFRWLQLQHDOFRKROWHVW
;
;























;
6HUXPSUHJQDQF\WHVWIHPDOHV
;
;
























8ULQHSUHJQDQF\WHVWIHPDOHV

























;
)6+SRVWPHQRSDXVDOZRPHQ
;

























&RQFRPLWDQWPHGLFDWLRQV
;
;
;
;
;
; ;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
$GYHUVHHYHQWVH
;
;
;
;
;
; ;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
;
'RVLQJI


;





;





;





;





3KDUPDFRNLQHWLFEORRGFROOHFWLRQJ


;
;
;
; ;

;
;
;
;
;

;
;
;
;
;

;
;
;
;
;

Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 39

3URWRFRO 3D&/ 9
7%$OOLDQFH
&21),'(17,$/
 'HF 
3DJH
D3K\VLFDO([DPLQDWLRQ)XOOSK\VLFDOH[DPLQDWLRQ DWVFUHHQLQJDQG DEEUHYLDWHGSK\VLFDO
H[DPLQDWLRQDW FKHFNLQ +HLJKWZLOORQO\EHFROOHFWHGDWVFUHHQLQJ
E9LWDO6LJQV0HDVXUHGDWFKHFNLQDQGZKLOHSDUWLFLSDQWVDUHFRQILQHGWRWKHFOLQLF RQFH SHU
GD\RUDV RWKHUZLVHQHHGHG>GHWHUPLQHGE\WKH,QYHVWLJDWRU@9LWDOVLJQVZLOOEHPHDVXUHG
ZLWKLQPLQXWHVSULRUWRGRVLQJDQGZLWKLQPLQXWHVRIWKHUHPDLQLQJGHILQHG
WLPHSRLQWV %RWKEORRGSUHVVXUH DQGKHDUWUDWHSXOVHVKRXOGEHFDSWXUHGVLPXOWDQHRXVO\
%ORRGSUHVVXUHDQGKHDUWUDWHVKRXOGEHPHDVXUHGDIWHUSDUWLFLSDQWVDUHLQDVHDWHGSRVLWLRQ
IRUDWOHDVWPLQXWHVDQGWKHQDJDLQDIWHUVWDQGLQJIRU PLQXWHH[FHSWZKHQWKH\DUH VXSLQH
RUVHPLUHFOLQHGEHFDXVHRIVWXG\SURFHGXUHVDQGRUDGYHUVHHYHQWVRUDVGHHPHGQHFHVVDU\
E\WKH,QYHVWLJDWRU
F(&*OHDGVDIHW\ (&*VZLOOEHSULQWHGDQGUHYLHZHGRQVLWHE\WKH3ULQFLSDO,QYHVWLJDWRU
RUGHVLJQHH6LQJOH(&*VZLOOEHREWDLQHGDW VFUHHQLQJDQGRQ6WXG\'D\VDQG
DQG PXVWEHSHUIRUPHGZLWKLQ KRXUVSULRUWRGRVLQJDQGFRPSOHWHGPLQXWHVSULRUWR
SUHGRVH EORRGGUDZ
G/DERUDWRU\6DIHW\$VVHVVPHQWV+DHPDWRORJ\KDHPRJORELQKDHPDWRFULWWRWDODQG
GLIIHUHQWLDOOHXNRF\WHFRXQWUHG EORRG FHOOFRXQWDQGSODWHOHW FRXQW6HUXPFKHPLVWU\
DOEXPLQEORRGXUHDQLWURJHQFUHDWLQLQHWRWDOELOLUXELQDONDOLQHSKRVSKDWDVHDVSDUWDWH
WUDQVDPLQDVHDODQLQHWUDQVDPLQDVHVRGLXPSRWDVVLXPFKORULGH ODFWDWHGHK\GURJHQDVH
FDOFLXPXULFDFLGJOXFRVH JDPPDJOXWDP\OWUDQVIHUDVHDQG PDJQHVLXP8ULQDO\VLVS+
VSHFLILFJUDYLW\SURWHLQJOXFRVHNHWRQHVELOLUXELQEORRG QLWULWHOHXNRF\WHHVWHUDVHDQG
XURELOLQRJHQ,I SURWHLQRFFXOWEORRGQLWULWH RUOHXNRF\WHHVWHUDVHYDOXHVDUHRXWRI UDQJHD
PLFURVFRSLFH[DPLQDWLRQZLOOEHSHUIRUPHG
H$GYHUVH(YHQWV $(V 3DUWLFLSDQWVZLOOEHPRQLWRUHGIRU$(V IURPWKH WLPHRIVLJQLQJWKH
LQIRUPHG FRQVHQWGRFXPHQWDQGWKURXJKRXWWKHVWXG\YLDVDIHW\DVVHVVPHQWVREVHUYDWLRQ
DQGSDUWLFLSDQWUHSRUWLQJ$VSHFLILFLQTXLU\UHJDUGLQJDGYHUVHHYHQWVZLOOEHFRQGXFWHG
SULRUWRGRVLQJDQGDWWLPHSRLQWVGHWHUPLQHGE\WKH,QYHVWLJDWRUSRVWGRVHDQGXSRQUHWXUQWR
FOLQLFIRUVXEVHTXHQWYLVLWV
I ,QYHVWLJDWLRQDO0HGLFLQDO 3URGXFW,03$GPLQLVWUDWLRQ6HH )LJXUH
J3KDUPDFRNLQHWLF3.6DPSOLQJ%ORRGVDPSOHVIRUDQDO\VLVRISUHWRPDQLGFRQFHQWUDWLRQV
ZLOOEHGUDZQMXVWEHIRUHGUXJLQWDNHSUHGRVHDQGDW
DQGKRXUVSRVWGRVHVDPSOHVSHULQWDNH'XSOLFDWH VDPSOHVZLOOEHFROOHFWHGIRU
DOOSODVPDSKDUPDFRNLQHWLFVDPSOHV
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 40

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH

5()(5(1&(6
 ,QYHVWLJDWRU¶V%URFKXUHIRU3UHWRPDQLG3$9HUVLRQ2FWREHU
*OREDO$OOLDQFHIRU7%'UXJ'HYHORSPHQW
 :+2*OREDO7%5HSRUWD
 :+2*OREDO7%5HSRUW
 /XQD-$&$WXEHUFXORVLVJXLGHIRUVSHFLDOLVWSK\VLFLDQV,QWHUQDWLRQDO8QLRQ
DJDLQVW7XEHUFXORVLVDQG/XQJ'LVHDVH
 &HQWHUVIRU'LVHDVH&RQWURODQG3UHYHQWLRQ)DFW6KHHW7UHQGVLQ
7XEHUFXORVLV$WODQWD*$86'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV
&'&6HSWHPEHU
 ³&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(YHUVLRQ´86
'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV1RYHPEHU
 ³*XLGDQFH)RU,QGXVWU\6WDWLVWLFDO$SSURDFKHVWR(VWDEOLVKLQJ%LRHTXLYDOHQFH´
86'HSDUWPHQWRI+HDOWKDQG+XPDQ6HUYLFHV)RRGDQG'UXJ$GPLQLVWUDWLRQ
&HQWHUIRU'UXJ(YDOXDWLRQDQG5HVHDUFK&'(5-DQXDU\
 ³*XLGDQFH)RU,QGXVWU\%LRDYDLODELOLW\DQG%LRHTXLYDOHQFH6WXGLHVIRU2UDOO\
$GPLQLVWHUHG'UXJ3URGXFWV*HQHUDO&RQVLGHUDWLRQV´86'HSDUWPHQWRI+HDOWK
DQG+XPDQ6HUYLFHV)RRGDQG'UXJ$GPLQLVWUDWLRQ&HQWHUIRU'UXJ(YDOXDWLRQ
DQG5HVHDUFK&'(50DUFK
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 41

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
$33(1',; 3+$50$&2.,1(7,&6$03/(&2//(&7,21352&(66,1*$1'
6+,30(17,16758&7,216
$ &ROOHFWLRQDQG3URFHVVLQJ
$PRUHGHWDLOHGGHVFULSWLRQRISODVPDVDPSOHSUHSDUDWLRQUHTXLUHPHQWVPD\EHSURYLGHGE\WKH
DQDO\WLFDOODERUDWRU\,IVXFKDGHVFULSWLRQLVSURYLGHGWKHPHWKRGRIVDPSOHSUHSDUDWLRQ
SURYLGHGE\WKHODERUDWRU\VKDOOVXSHUVHGHWKRVHSURYLGHGLQWKLVSURWRFRODQGDSSURSULDWH
GRFXPHQWDWLRQVKDOOEHSODFHGLQWKH,QYHVWLJDWRU6LWH)LOH,6)
3URFHVVLQJ,QVWUXFWLRQV

%ORRGVDPSOHVZLOOEHFROOHFWHGLQWRP/9DFXWDLQHUWXEHVFRQWDLQLQJ.('7$
7KHWLPHDQGGDWHRIFROOHFWLRQIRUHDFKVDPSOHZLOOEHUHFRUGHG

'XULQJHDFKWUHDWPHQWSHULRGVDPSOHVZLOOEHFROOHFWHGDWKRXUSUHGRVHZLWKLQ
PLQXWHVEHIRUHWKHGRVHRIVWXG\GUXJDQGDW
DQGKRXUVSRVWGRVH
1RWH3UHGRVHEORRGVDPSOHVREWDLQHGIURPEDFNXSVXEMHFWVZKRDUHUDQGRPL]HG
LQWRWKHVWXG\PD\H[FHHGWKHSUHGRVHFROOHFWLRQZLQGRZ

%ORRGVDPSOHVZLOOEHFHQWULIXJHGDWDSSUR[LPDWHO\USPIRUPLQXWHVDW
DSSUR[LPDWHO\GHJUHHV&HQWLJUDGH

7KHUHVXOWLQJSODVPDVDPSOHVZLOOEHKDUYHVWHGDQGWUDQVIHUUHGLQDSSUR[LPDWHO\
HTXDODOLTXRWVLQWRWZRDSSURSULDWHO\ODEHOHGSRO\SURS\OHQHVFUHZFDSWXEHV

6DPSOHVZLOOEHSODFHGLQDQXSULJKWSRVLWLRQLQDIUHH]HUDWDSSUR[LPDWHO\
GHJUHHV&HQWLJUDGHZLWKLQPLQXWHVRIFROOHFWLRQ

6DPSOHVZLOOUHPDLQIUR]HQXQWLODVVD\HG

6DPSOH&ROOHFWLRQ6XPPDU\
1XPEHU
RI
VXEMHFWV
1XPEHURI
WLPHSRLQWV
SHUSHULRG
1XPEHU
RISHULRGV
6DPSOHW\SH
7XEHW\SH
1XPEHURIWXEHVSHU
WLPHSRLQW



&ROOHFWLRQ
P/.('7$
9DFXWDLQHU

$OLTXRW
X/3RO\SURS\OHQH
VFUHZ&DS

Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 42

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
% /DEHOLQJRIDOLTXRWWXEHV
/DEHOVZLOOFRQWDLQDWOHDVWWKHIROORZLQJLQIRUPDWLRQ
D6WXG\QXPEHU
E6XEMHFWLGHQWLILFDWLRQ
F3HULRGRUGRVLQJSKDVHVDPSOLQJWLPHUHODWLYHWRGRVLQJ
G$OLTXRWOHWWHUDRUE
& 6KLSPHQW
 7KHVDPSOHVZLOOEHWUDQVIHUUHGWRWKHDQDO\WLFDOODERUDWRU\DIWHUFRPSOHWLRQRIWKH
VWXG\RUDWPXWXDOO\DJUHHGXSRQWLPHSRLQWVGXULQJWKHFOLQLFDOFRQGXFWRIWKHVWXG\
7KHVHFRQGVHWRIVDPSOHVZLOOEHVKLSSHGDIWHUWKHELRDQDO\WLFDOODERUDWRU\FRQILUPV
UHFHLSWRIWKHILUVWVHWRIVDPSOHV
 6DPSOHVZLOOEHSDFNDJHGLQWRFU\RER[HVDQGVRUWHGE\VXEMHFW
 %HIRUHVKLSPHQWWKHVDPSOHVZLOOEHDSSURSULDWHO\SDFNHGLQDFRROHUFRQWDLQLQJGU\
LFH6XIILFLHQWGU\LFHZLOOEHDGGHGWRHQVXUHWKDWWKHVDPSOHVZLOOUHPDLQIUR]HQIRUDW
OHDVWKRXUV
 $QHOHFWURQLFPDQLIHVWZLOOEHSURYLGHGLQDGYDQFH7KHVKLSPHQWZLOOEHDFFRPSDQLHG
E\GRFXPHQWDWLRQFRQWDLQLQJWKHIROORZLQJLQIRUPDWLRQQDPHRIWKHVWXG\GUXJ
SURGXFWSURWRFROQXPEHUQXPEHURIVXEMHFWVDQGQXPEHURIVDPSOHVLQFOXGHGLQWKH
VKLSPHQW([SHFWHGVDPSOHVWKDWDUHQRWSUHVHQWZLOOEHLGHQWLILHG
 $OOIUR]HQSKDUPDFRNLQHWLFVDPSOHVZLOOEHWUDQVIHUUHGZLWKDFFRPSDQ\LQJ
GRFXPHQWDWLRQWR
$OOLDQFH3KDUPD
/HH%RXOHYDUG
0DOYHUQ3HQQV\OYDQLD
7HOHSKRQH
&RQWDFWQDPH0LFKHOOH%ODFN
(PDLOVDPSOHV#DOOLDQFHSKDUPDFRFRP


PEODFN#DOOLDQFHSKDUPDFRFRP
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 43

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
$33(1',;',9,6,212)0,&52%,2/2*<$1',1)(&7,286',6($6(
72;,&,7<7$%/(
'LYLVLRQRI0LFURELRORJ\DQG,QIHFWLRXV'LVHDVH'0,'7R[LFLW\7DEOH
6RXUFH861DWLRQDO,QVWLWXWHRI$OOHUJ\DQG,QIHFWLRXV'LVHDVHV'0,'1RYHPEHU
'UDIW
$%%5(9,$7,216$EEUHYLDWLRQVXWLOL]HGLQWKH7DEOH
8/1 8SSHU/LPLWRI1RUPDO
//1 /RZHU/LPLWRI1RUPDO
5[ 7KHUDS\
5HT 5HTXLUHG
0RG 0RGHUDWH
,9 ,QWUDYHQRXV
$'/ $FWLYLWLHVRI'DLO\/LYLQJ
'HF 'HFUHDVHG

(67,0$7,1*6(9(5,7<*5$'(
)RUDEQRUPDOLWLHV127IRXQGHOVHZKHUHLQWKH7R[LFLW\7DEOHVXVHWKHVFDOHEHORZWRHVWLPDWH
JUDGHRIVHYHULW\
*UDGH
6HYHULW\5DWLQJ
'HILQLWLRQ
*5$'(
0LOG
7UDQVLHQWRUPLOGGLVFRPIRUWKRXUVQRPHGLFDO
LQWHUYHQWLRQWKHUDS\UHTXLUHG
*5$'(
0RGHUDWH
0LOGWRPRGHUDWHOLPLWDWLRQLQDFWLYLW\VRPHDVVLVWDQFHPD\EH
QHHGHGQRRUPLQLPDOPHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHG
*5$'(
6HYHUH
0DUNHGOLPLWDWLRQLQDFWLYLW\VRPHDVVLVWDQFHXVXDOO\UHTXLUHG
PHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHGKRVSLWDOL]DWLRQVSRVVLEOH
*5$'(
3RWHQWLDOO\/LIH
WKUHDWHQLQJ
([WUHPHOLPLWDWLRQLQDFWLYLW\VLJQLILFDQWDVVLVWDQFHUHTXLUHG
VLJQLILFDQWPHGLFDOLQWHUYHQWLRQWKHUDS\UHTXLUHGKRVSLWDOL]DWLRQRU
KRVSLFHFDUHSUREDEOH

6(5,28625/,)(7+5($7(1,1*$(V
$1<FOLQLFDOHYHQWGHHPHGE\WKHFOLQLFLDQWREHVHULRXVRUOLIHWKUHDWHQLQJVKRXOGEH
FRQVLGHUHGDJUDGHHYHQW&OLQLFDOHYHQWVFRQVLGHUHGWREHVHULRXVRUOLIHWKUHDWHQLQJLQFOXGH
EXWDUHQRWOLPLWHGWRVHL]XUHVFRPDWHWDQ\GLDEHWLFNHWRDFLGRVLVGLVVHPLQDWHGLQWUDYDVFXODU
FRDJXODWLRQGLIIXVHSHWHFKLDHSDUDO\VLVDFXWHSV\FKRVLVVHYHUHGHSUHVVLRQ
&200(1765(*$5',1*7+(86(2)7+(6(7$%/(6
x 6WDQGDUGL]HGDQGFRPPRQO\XVHGWR[LFLW\WDEOHV'LYLVLRQRI$,'61&,¶V&RPPRQ
7R[LFLW\&ULWHULD&7&DQG:RUOG+HDOWK2UJDQL]DWLRQ:+2KDYHEHHQDGDSWHGIRUXVH
E\WKH'LYLVLRQRI0LFURELRORJ\DQG,QIHFWLRXV'LVHDVHV'0,'DQGPRGLILHGWREHWWHU
PHHWWKHQHHGVRI3DWLHQWVLQ'0,'WULDOV
x )RUSDUDPHWHUVQRWLQFOXGHGLQWKHIROORZLQJ7R[LFLW\7DEOHVVLWHVVKRXOGUHIHUWRWKH³*XLGH
)RU(VWLPDWLQJ6HYHULW\*UDGH´ORFDWHGDERYH
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 44

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
x &ULWHULDDUHJHQHUDOO\JURXSHGE\ERG\V\VWHP
x 6RPHSURWRFROVPD\KDYHDGGLWLRQDOSURWRFROVSHFLILFJUDGLQJFULWHULDZKLFKZLOOVXSHUVHGH
WKHXVHRIWKHVHWDEOHVIRUVSHFLILHGFULWHULD
+(0$72/2*<

*UDGH
*UDGH
*UDGH
*UDGH
+HPRJORELQ
JPG/
JPG/
JPG/
JPG/
$EVROXWH1HXWURSKLO
&RXQW
PP
PP
PP
PP
3ODWHOHWV
PP
PP
PP
PP
:%&V

PP

PP
PP
!RU
PP
3RO\PRUSKRQXFOHDU
/HXFRF\WHV%DQG
&HOOV
!
±
!

$EQRUPDO)LEULQRJHQ
/RZ
PJG/
+LJK
PJG/
/RZ
PJG/
+LJK
!PJG/
/RZ
PJG/


)LEULQRJHQ
DVVRFLDWHGZLWK
JURVVEOHHGLQJRU
ZLWKGLVVHPLQDWHG
FRDJXODWLRQ
)LEULQ6SOLW3URGXFW
PFJPO
PFJPO
PFJPO
!PFJPO
3URWKURPELQ7LPH37
[8/1
[8/1
[8/1
![8/1
$FWLYDWHG3DUWLDO
7KURPERSODVWLQ$337
[8/1
[8/1
[8/1
![8/1
0HWKHPRJORELQ



!

&+(0,675,(6

*UDGH
*UDGH
*UDGH
*UDGH
+\SRQDWUHPLD
P(T/
P(T/
P(T/
P(T/RUDEQRUPDO
VRGLXPZLWKPHQWDOVWDWXV
FKDQJHVRUVHL]XUHV
+\SHUQDWUHPLD
P(T/
P(T/
P(T/
!P(T/RUDEQRUPDO
VRGLXPZLWKPHQWDOVWDWXV
FKDQJHVRUVHL]XUHV
+\SRNDOHPLD
P(T/
P(T/
P(T/RU
LQWHQVLYH
UHSODFHPHQW
WKHUDS\RU
KRVSLWDOL]DWLRQ
UHTXLUHG
P(T/RUDEQRUPDO
SRWDVVLXPZLWKSDUHVLVLOHXV
RUOLIHWKUHDWHQLQJDUUK\WKPLD
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 45

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
&+(0,675,(6

*UDGH
*UDGH
*UDGH
*UDGH
+\SHUNDOHPLD
P(T/
P(T/
P(TO
!P(T/RUDEQRUPDO
SRWDVVLXPZLWKOLIH
WKUHDWHQLQJDUUK\WKPLD
+\SRJO\FHPLD
PJG/
PJG/
PJG/
PJG/RUDEQRUPDO
JOXFRVHZLWKPHQWDOVWDWXV
FKDQJHVRUFRPD
+\SHUJO\FHPLD
QRQIDVWLQJDQGQR
SULRUGLDEHWHV
PJG/
PJG/
PJG/
!PJG/RUDEQRUPDO
JOXFRVHZLWKNHWRDFLGRVLVRU
VHL]XUHV
+\SRFDOFHPLD
FRUUHFWHGIRU
DOEXPLQ
PJG/
PJG/
PJG/
PJG/RUDEQRUPDO
FDOFLXPZLWKOLIHWKUHDWHQLQJ
DUUK\WKPLDRUWHWDQ\
+\SHUFDOFHPLD
FRUUHFWIRUDOEXPLQ
PJG/

PJG/
PJG/
!PJG/RUDEQRUPDO
FDOFLXPZLWKOLIHWKUHDWHQLQJ
DUUK\WKPLD
+\SRPDJQHVHPLD
P(T/
P(T/
P(T/
P(T/RUDEQRUPDO
PDJQHVLXPZLWKOLIH
WKUHDWHQLQJDUUK\WKPLD
+\SRSKRVSKDWHPLD
PJG/
PJG/
RUUHSODFHPHQW
5[UHTXLUHG
PJG/
LQWHQVLYHWKHUDS\RU
KRVSLWDOL]DWLRQ
UHTXLUHG
PJG/RUDEQRUPDO
SKRVSKDWHZLWKOLIH
WKUHDWHQLQJDUUK\WKPLD
+\SHUELOLUXELQHPLD
ZKHQDFFRPSDQLHG
E\DQ\LQFUHDVHLQ
RWKHUOLYHUIXQFWLRQ
WHVW
[8/1
[
8/1
±[8/1
![8/1
+\SHUELOLUXELQHPLD
ZKHQRWKHUOLYHU
IXQFWLRQDUHLQWKH
QRUPDOUDQJH
[8/1
[8/1
±[8/1
![8/1
%81
[8/1
[8/1
[8/1
![8/1
+\SHUXULFHPLDXULF
DFLG
±PJG/
±
PJG/
±PJG/
!PJG/
&UHDWLQLQH
[8/1
[8/1
[8/1
![8/1RUGLDO\VLV
UHTXLUHG

(1=<0(6

*UDGH
*UDGH
*UDGH
*UDGH
$676*27
[8/1
±[8/1
±[8/1
![8/1
$/76*37
[8/1
±[8/1
±[8/1
![8/1
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 46

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
(1=<0(6

*UDGH
*UDGH
*UDGH
*UDGH
**7
[8/1
±[8/1
±[8/1
![8/1
$ONDOLQH3KRVSKDWDVH
[8/1
±[8/1
±[8/1
![8/1
$P\ODVH
[8/1
[8/1
[8/1
![8/1
/LSDVH
[8/1
[8/1
[8/1
![8/1

85,1$/<6,6

*UDGH
*UDGH
*UDGH
*UDGH
3URWHLQXULD
RUPJ
JPORVVGD\
RUJP
ORVVGD\
RUJP
ORVVGD\
QHSKURWLFV\QGURPH
RU!JP
ORVVGD\
+HPDWXULD
PLFURVFRSLFRQO\
UEFKSI
JURVVQRFORWV!
UEFKSI
JURVVZLWKRU
ZLWKRXWFORWV25
UHGEORRGFHOOFDVWV
REVWUXFWLYHRU
UHTXLUHGWUDQVIXVLRQ
$VVHVVPHQWGRHVQRWDSSO\LIDVXEMHFWLVRQPHQVHV
&$5',29$6&8/$5

*UDGH
*UDGH
*UDGH
*UDGH
&DUGLDF5K\WKP

DV\PSWRPDWLF
WUDQVLHQWVLJQVQR
5[UHTXLUHG
UHFXUUHQWSHUVLVWHQW
V\PSWRPDWLF5[
UHTXLUHG
XQVWDEOH
G\VU\WKPLD
KRVSLWDOL]DWLRQDQG
WUHDWPHQWUHTXLUHG
+\SHUWHQVLRQ
WUDQVLHQWLQFUHDVH
!PP+JQR
WUHDWPHQW
UHFXUUHQWFKURQLF
LQFUHDVH!
PP+J
WUHDWPHQWUHTXLUHG
DFXWHWUHDWPHQW
UHTXLUHGRXWSDWLHQW
WUHDWPHQWRU
KRVSLWDOL]DWLRQ
SRVVLEOH
HQGRUJDQGDPDJH
RUKRVSLWDOL]DWLRQ
UHTXLUHG
+\SRWHQVLRQ
WUDQVLHQW
RUWKRVWDWLF
K\SRWHQVLRQZLWK
KHDUWUDWH
LQFUHDVHGE\
EHDWPLQRU
GHFUHDVHGE\
PP+JV\VWROLF
%31RWUHDWPHQW
UHTXLUHG
V\PSWRPVGXHWR
RUWKRVWDWLF
K\SRWHQVLRQRU%3
GHFUHDVHGE\
PP+JV\VWROLF
FRUUHFWDEOHZLWKRUDO
IOXLGWUHDWPHQW
UHTXLUHV,9IOXLGVQR
KRVSLWDOL]DWLRQ
UHTXLUHG
PHDQDUWHULDO
SUHVVXUHPP
+JRUHQGRUJDQ
GDPDJHRUVKRFN
UHTXLUHV
KRVSLWDOL]DWLRQDQG
YDVRSUHVVRU
WUHDWPHQW
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 47

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
&$5',29$6&8/$5

*UDGH
*UDGH
*UDGH
*UDGH
3HULFDUGLWLV
PLQLPDOHIIXVLRQ
PLOGPRGHUDWH
DV\PSWRPDWLF
HIIXVLRQQR
WUHDWPHQW
V\PSWRPDWLF
HIIXVLRQSDLQ(.*
FKDQJHV
WDPSRQDGH
SHULFDUGLRFHQWHVLV
RUVXUJHU\UHTXLUHG
+HPRUUKDJH%ORRG
/RVV
PLFURVFRSLFRFFXOW
PLOGQRWUDQVIXVLRQ
JURVVEORRGORVV
XQLWVWUDQVIXVHG
PDVVLYHEORRG
ORVV!XQLWV
WUDQVIXVHG
)RUSURWRFRO7%,&/GHILQHGDVLQFUHDVHIURPEDVHOLQHLQSUHGRVHYLWDOVLJQV

5(63,5$725<

*UDGH
*UDGH
*UDGH
*UDGH
&RXJK
7UDQVLHQWQR
WUHDWPHQW
SHUVLVWHQWFRXJK
WUHDWPHQWUHVSRQVLYH
3DUR[\VPDOFRXJK
XQFRQWUROOHGZLWK
WUHDWPHQW

%URQFKRVSDVP
$FXWH
WUDQVLHQWQR
WUHDWPHQW
)(9RISHDN
IORZ
UHTXLUHVWUHDWPHQW
QRUPDOL]HVZLWK
EURQFKRGLODWRU)(9
RISHDN
IORZ
QRQRUPDOL]DWLRQZLWK
EURQFKRGLODWRU)(9
RISHDN
IORZRUUHWUDFWLRQV
SUHVHQW
F\DQRVLV)(9
RISHDNIORZ
RULQWXEDWLRQ
QHFHVVDU\
'\VSQHD
G\VSQHDRQH[HUWLRQ
G\VSQHDZLWKQRUPDO
DFWLYLW\
G\VSQHDDWUHVW
G\VSQHDUHTXLULQJ
2[\JHQWKHUDS\

*$6752,17(67,1$/

*UDGH
*UDGH
*UDGH
*UDGH
1DXVHD
PLOGRUWUDQVLHQW
PDLQWDLQV
UHDVRQDEOHLQWDNH
PRGHUDWH
GLVFRPIRUWLQWDNH
GHFUHDVHG
VLJQLILFDQWO\VRPH
DFWLYLW\OLPLWHG
QRVLJQLILFDQW
LQWDNHUHTXLUHV,9
IOXLGV
KRVSLWDOL]DWLRQ
UHTXLUHG
9RPLWLQJ
HSLVRGHLQ
KRXUV
HSLVRGHVLQ
KRXUV
!HSLVRGHVLQ
KRXUVRUQHHGLQJ,9
IOXLGV
SK\VLRORJLF
FRQVHTXHQFHV
UHTXLULQJ
KRVSLWDOL]DWLRQRU
UHTXLULQJSDUHQWHUDO
QXWULWLRQ
&RQVWLSDWLRQ
UHTXLULQJVWRRO
VRIWHQHURUGLHWDU\
PRGLILFDWLRQ
UHTXLULQJOD[DWLYHV
REVWLSDWLRQ
UHTXLULQJPDQXDO
HYDFXDWLRQRU
HQHPD
REVWUXFWLRQRUWR[LF
PHJDFRORQ
'LDUUKHD
PLOGRUWUDQVLHQW
ORRVHVWRROVGD\
RUPLOGGLDUUKHD
PRGHUDWHRU
SHUVLVWHQWORRVH
VWRROVGD\RU
!ORRVHVWRROVGD\
RUEORRG\GLDUUKHD
RURUWKRVWDWLF
K\SRWHQVLYHVKRFN
RUSK\VLRORJLF
FRQVHTXHQFHV
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 48

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
*$6752,17(67,1$/

*UDGH
*UDGH
*UDGH
*UDGH
ODVWZHHN
GLDUUKHDODVWLQJ!
ZHHN
K\SRWHQVLRQRU
HOHFWURO\WH
LPEDODQFHRU!/
,9IOXLGVUHTXLUHG
UHTXLULQJ
KRVSLWDOL]DWLRQ
2UDO
'LVFRPIRUW'\VSKDJLD
PLOGGLVFRPIRUWQR
GLIILFXOW\VZDOORZLQJ
VRPHOLPLWVRQ
HDWLQJGULQNLQJ
HDWLQJWDONLQJYHU\
OLPLWHGXQDEOHWR
VZDOORZVROLGIRRGV
XQDEOHWRGULQN
IOXLGVUHTXLUHV,9
IOXLGV

1(852/2*,&$/

*UDGH
*UDGH
*UDGH
*UDGH
1HXUR&HUHEHOODU
VOLJKW
LQFRRUGLQDWLRQ
G\VGLDGRFKRNLQHVLV
LQWHQWLRQWUHPRU
G\VPHWULDVOXUUHG
VSHHFKQ\VWDJPXV
ORFRPRWRUDWD[LD
LQFDSDFLWDWHG
3V\FKLDWULF
PLOGDQ[LHW\RU
GHSUHVVLRQ
PRGHUDWHDQ[LHW\RU
GHSUHVVLRQWKHUDS\
UHTXLUHGFKDQJHLQ
QRUPDOURXWLQH
VHYHUHPRRG
FKDQJHVUHTXLULQJ
WKHUDS\RUVXLFLGDO
LGHDWLRQRU
DJJUHVVLYHLGHDWLRQ
DFXWHSV\FKRVLV
UHTXLULQJ
KRVSLWDOL]DWLRQRU
VXLFLGDO
JHVWXUHDWWHPSWRU
KDOOXFLQDWLRQV
0XVFOH6WUHQJWK
6XEMHFWLYH
ZHDNQHVVQR
REMHFWLYH
V\PSWRPVVLJQV
PLOGREMHFWLYH
VLJQVV\PSWRPVQR
GHFUHDVHLQIXQFWLRQ
REMHFWLYHZHDNQHVV
IXQFWLRQOLPLWHG
SDUDO\VLV
3DUHVWKHVLDEXUQLQJ
WLQJOLQJHWF
PLOGGLVFRPIRUWQR
WUHDWPHQWUHTXLUHG
PRGHUDWH
GLVFRPIRUWQRQ
QDUFRWLFDQDOJHVLD
UHTXLUHG
VHYHUHGLVFRPIRUW
RUQDUFRWLF
DQDOJHVLDUHTXLUHG
ZLWKV\PSWRPDWLF
LPSURYHPHQW
LQFDSDFLWDWLQJRU
QRWUHVSRQVLYHWR
QDUFRWLFDQDOJHVLD
1HXURVHQVRU\
PLOGLPSDLUPHQWLQ
VHQVDWLRQ
GHFUHDVHG
VHQVDWLRQHJ
YLEUDWRU\SLQSULFN
KRWFROGLQJUHDW
WRHVLQIRFDODUHD
RUV\PPHWULFDO
GLVWULEXWLRQRU
FKDQJHLQWDVWH
VPHOOYLVLRQDQGRU
KHDULQJ
PRGHUDWH
LPSDLUPHQWPRG
GHFUHDVHG
VHQVDWLRQHJ
YLEUDWRU\SLQSULFN
KRWFROGWRDQNOHV
DQGRUMRLQWSRVLWLRQ
RUPLOGLPSDLUPHQW
WKDWLVQRW
V\PPHWULFDO
VHYHUHLPSDLUPHQW
GHFUHDVHGRUORVV
RIVHQVDWLRQWR
NQHHVRUZULVWVRU
ORVVRIVHQVDWLRQRI
DWOHDVWPRG
GHJUHHLQPXOWLSOH
GLIIHUHQWERG\
DUHDVLHXSSHU
DQGORZHU
H[WUHPLWLHV
VHQVRU\ORVV
LQYROYHVOLPEVDQG
WUXQNSDUDO\VLVRU
VHL]XUHV



Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 49

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
086&8/26.(/(7$/

*UDGH
*UDGH
*UDGH
*UDGH
$UWKUDOJLDMRLQWSDLQ
PLOGSDLQQRW
LQWHUIHULQJZLWK
IXQFWLRQ
PRGHUDWHSDLQ
DQDOJHVLFVDQGRU
SDLQLQWHUIHULQJZLWK
IXQFWLRQEXWQRWZLWK
DFWLYLWLHVRIGDLO\
OLYLQJ
VHYHUHSDLQSDLQ
DQGRUDQDOJHVLFV
LQWHUIHULQJZLWK
DFWLYLWLHVRIGDLO\
OLYLQJ
GLVDEOLQJSDLQ
$UWKULWLV
PLOGSDLQZLWK
LQIODPPDWLRQ
HU\WKHPDRUMRLQW
VZHOOLQJ±EXWQRW
LQWHUIHULQJZLWK
IXQFWLRQ
PRGHUDWHSDLQZLWK
LQIODPPDWLRQ
HU\WKHPDRUMRLQW
VZHOOLQJ±LQWHUIHULQJ
ZLWKIXQFWLRQEXWQRW
ZLWKDFWLYLWLHVRI
GDLO\OLYLQJ
VHYHUHSDLQZLWK
LQIODPPDWLRQ
HU\WKHPDRUMRLQW
VZHOOLQJ±DQG
LQWHUIHULQJZLWK
DFWLYLWLHVRIGDLO\
OLYLQJ
SHUPDQHQWDQGRU
GLVDEOLQJMRLQW
GLVWUXFWLRQ
0\DOJLD
P\DOJLDZLWKQR
OLPLWDWLRQRIDFWLYLW\
PXVFOHWHQGHUQHVV
DWRWKHUWKDQ
LQMHFWLRQVLWHRUZLWK
PRGHUDWH
LPSDLUPHQWRI
DFWLYLW\
VHYHUHPXVFOH
WHQGHUQHVVZLWK
PDUNHGLPSDLUPHQW
RIDFWLYLW\
IUDQN
P\RQHFURVLV

6.,1

*UDGH
*UDGH
*UDGH
*UDGH
0XFRFXWDQHRXV
HU\WKHPDSUXULWXV
GLIIXVHPDFXOR
SDSXODUUDVKGU\
GHVTXDPDWLRQ
YHVLFXODWLRQRUPRLVW
GHVTXDPDWLRQRU
XOFHUDWLRQ
H[IROLDWLYHGHUPDWLWLV
PXFRXVPHPEUDQH
LQYROYHPHQWRU
HU\WKHPD
PXOWLIRUPHRU
VXVSHFWHG6WHYHQV
-RKQVRQRUQHFURVLV
UHTXLULQJVXUJHU\
,QGXUDWLRQ
PP
PP
!PP

(U\WKHPD
PP
PP
!PP

(GHPD
PP
PP
!PP

5DVKDW,QMHFWLRQ
6LWH
PP
PP
!PP

3UXULWXV
VOLJKWLWFKLQJDW
LQMHFWLRQVLWH
PRGHUDWHLWFKLQJDW
LQMHFWLRQH[WUHPLW\
LWFKLQJRYHUHQWLUH
ERG\



Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 50

3URWRFRO3D&/9

7%$OOLDQFH
&21),'(17,$/
'HF
3DJH
6<67(0,&

*UDGH
*UDGH
*UDGH
*UDGH
$OOHUJLF5HDFWLRQ
SUXULWXVZLWKRXWUDVK
ORFDOL]HGXUWLFDULD
JHQHUDOL]HGXUWLFDULD
DQJLRHGHPD
DQDSK\OD[LV
+HDGDFKH
PLOGQRWUHDWPHQW
UHTXLUHG
WUDQVLHQWPRGHUDWH
WUHDWPHQWUHTXLUHG
VHYHUHUHVSRQGVWR
LQLWLDOQDUFRWLF
WKHUDS\
LQWUDFWDEOHUHTXLUHV
UHSHDWHGQDUFRWLF
WKHUDS\
)HYHURUDO
&RU
)
&RU
)
&RU
)
!&RU!)
)DWLJXH
QRUPDODFWLYLW\
UHGXFHGKRXUV
QRUPDODFWLYLW\
GHFUHDVHG
!KRXUV
QRUPDODFWLYLW\
GHFUHDVHG!
FDQ¶WZRUN
XQDEOHWRFDUHIRU
VHOI



Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 51

3URWRFRO1XPEHU3D&/
3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH
3DJHRI
'HF
3URWRFRO&ODULILFDWLRQ/HWWHU
7%$OOLDQFH3URWRFRO3D&/$Q2SHQODEHO5DQGRPL]HG)RXUSHULRG&URVVRYHU
6WXG\LQ7ZR3DQHOVRI+HDOWK\$GXOW3DUWLFLSDQWVWR$VVHVVWKH5HODWLYH%LRDYDLODELOLW\)RRG
(IIHFWDQG'RVHGHSHQGHQFHRI6LQJOH'RVH,PPHGLDWH5HOHDVHDQG6LQJOHGRVH'LVSHUVLEOH
)RUPXODWLRQVRI3UHWRPDQLG
7KHSXUSRVHRIWKLVOHWWHULVWRFODULI\WKHWKDWUHWHQWLRQVDPSOHVDUHQRWQHHGHG
7KHVHFWLRQRISURWRFROYHUVLRQGDWHG'HFDIIHFWHGE\ WKLVFKDQJHLVLQGLFDWHG
EHORZ
3URWRFRO3DJH6HFWLRQ'UXJ6XSSOLHV3DUDJUDSK
&XUUHQWO\UHDGV
6XIILFLHQWTXDQWLWLHVRIVWXG\GUXJZLOOEHVXSSOLHGWRDOORZIRUUHWHQWLRQVDPSOHV5HWHQWLRQ
VDPSOHVZLOOEHVWRUHGDWWKHFOLQLFDOVLWHSXUVXDQWWRWKHVLWH623V7KHVLWHZLOOEHUHVSRQVLEOH
IRUUDQGRPO\VHOHFWLQJGRVHVWREHDGPLQLVWHUHGDQGGRVHVWREHUHWDLQHG$WWKHFRQFOXVLRQRI
WKHVWXG\DQ\XQXVHGVWXG\GUXJQRWLQFOXGLQJUHWHQWLRQVDPSOHVZLOOEHUHWXUQHGWRWKH
VSRQVRURUGHVWUR\HGE\WKHVLWHSXUVXDQWWRZULWWHQDXWKRUL]DWLRQE\WKHVSRQVRUDQGDSSOLFDEOH
IHGHUDODQGVWDWHUHJXODWLRQV
5HYLVHGWRUHDG
5HWHQWLRQVDPSOHVRIWKHLQYHVWLJDWLRQDOVWXG\GUXJZLOOQRWEHUHTXLUHG$WWKHFRQFOXVLRQ
RIWKHVWXG\DQ\XQXVHGVWXG\GUXJZLOOEHUHWXUQHGWRWKHVSRQVRURUGHVWUR\HGE\WKHVLWH
SXUVXDQWWRZULWWHQDXWKRUL]DWLRQE\WKHVSRQVRUDQGDSSOLFDEOHIHGHUDODQGVWDWHUHJXODWLRQV
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 52

3URWRFRO1XPEHU3D&/
3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH
3DJHRI
'HF
$SSURYHG%\
6SRQVRU&RQWDFW
)UDQFHV3DSSDV
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH
'DWH
0HGLFDO2IILFHU
$QWRQLR7RQ\/RPEDUGL0'
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH
'DWH
3ULQFLSDO,QYHVWLJDWRU
&\QWKLD$=DPRUD0'
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&
1(/RRS6XLWH
6DQ$QWRQLR7H[DV
3KRQH
6LJQDWXUH
'DWH
 
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 53

3URWRFRO1XPEHU3D&/
3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH
3DJHRI
'HF
3URWRFRO&ODULILFDWLRQ/HWWHU
7%$OOLDQFH3URWRFRO3D&/$Q2SHQODEHO5DQGRPL]HG)RXUSHULRG&URVVRYHU
6WXG\LQ7ZR3DQHOVRI+HDOWK\$GXOW3DUWLFLSDQWVWR$VVHVVWKH5HODWLYH%LRDYDLODELOLW\)RRG
(IIHFWDQG'RVHGHSHQGHQFHRI6LQJOH'RVH,PPHGLDWH5HOHDVHDQG6LQJOHGRVH'LVSHUVLEOH
)RUPXODWLRQVRI3UHWRPDQLG
7KHSXUSRVHRIWKLVOHWWHULVWRFODULI\WZRH[FOXVLRQFULWHULDDQGDGGDWDVWHHYDOXDWLRQSRVWGRVH
7KHVHFWLRQRISURWRFROYHUVLRQGDWHG'HFDIIHFWHGE\ WKLVFKDQJHLVLQGLFDWHG
EHORZ
3URWRFRO3DJH6HFWLRQ([FOXVLRQ
&XUUHQWO\UHDGV
$FOLQLFDOO\VLJQLILFDQWDEQRUPDOILQGLQJRQWKHSK\VLFDOH[DPLQDWLRQPHGLFDOKLVWRU\
HOHFWURFDUGLRJUDP(&*RUFOLQLFDOODERUDWRU\UHVXOWV
5HYLVHGWRUHDG
$FOLQLFDOO\VLJQLILFDQWDEQRUPDOILQGLQJRQWKHSK\VLFDOH[DPLQDWLRQPHGLFDOKLVWRU\
HOHFWURFDUGLRJUDP(&*RUFOLQLFDOODERUDWRU\UHVXOWVHJODERUDWRU\SURILOHVDUHQRUPDOXS
WRDQGLQFOXGLQJ*UDGHSHU'0,'WR[LFLW\WDEOHV
3URWRFRO3DJH6HFWLRQ([FOXVLRQ
&XUUHQWO\UHDGV
8VHRIDQ\RYHUWKHFRXQWHU27&PHGLFDWLRQLQFOXGLQJQXWULWLRQDORUGLHWDU\VXSSOHPHQWV
KHUEDOSUHSDUDWLRQVRUYLWDPLQVZLWKLQGD\VEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQXQWLOWKH
HQGRIVWXG\YLVLWZLWKRXWHYDOXDWLRQDQGDSSURYDOE\WKH,QYHVWLJDWRU8SWRJUDPVSHUGD\RI
DFHWDPLQRSKHQLVDOORZHGDWWKHGLVFUHWLRQRIWKH,QYHVWLJDWRUSULRUWRGRVLQJ
5HYLVHGWRUHDG
8VHRIDQ\RYHUWKHFRXQWHU27&PHGLFDWLRQLQFOXGLQJQXWULWLRQDORUGLHWDU\VXSSOHPHQWV
KHUEDOSUHSDUDWLRQVRUYLWDPLQVZLWKLQGD\VEHIRUHWKHILUVWGRVHRIVWXG\PHGLFDWLRQXQWLOWKH
HQGRIVWXG\YLVLWZLWKRXWHYDOXDWLRQDQGDSSURYDOE\WKH,QYHVWLJDWRU2FFDVLRQDOXVHRIXSWR
JUDPVSHUGD\RIDFHWDPLQRSKHQLVDOORZHGDWWKHGLVFUHWLRQRIWKH,QYHVWLJDWRUSULRUWRGRVLQJ
3URWRFRO3DJH6HFWLRQ7DEOH6FKHGXOHRI$VVHVVPHQWVDQG3URFHGXUHV
$GG³7DVWHHYDOXDWLRQK´WR7DEOHZLWKWKHIROORZLQJIRRWQRWH
K 7DVWHHYDOXDWLRQZLOOEHFRQGXFWHGLPPHGLDWHO\DIWHUGRVLQJDQGPLQXWHVDIWHU
DGPLQLVWUDWLRQWRGHWHUPLQHDQ\DIWHUWDVWH
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 54

3URWRFRO1XPEHU3D&/
3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH
3DJHRI
'HF
$SSURYHG%\
6SRQVRU&RQWDFW
)UDQFHV3DSSDV
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH
'DWH
0HGLFDO2IILFHU
$QWRQLR7RQ\/RPEDUGL0'
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH
'DWH
3ULQFLSDO,QYHVWLJDWRU
&\QWKLD$=DPRUD0'
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&
1(/RRS6XLWH
6DQ$QWRQLR7H[DV
3KRQH
6LJQDWXUH
'DWH
 
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 55

3URWRFRO1XPEHU3D&/
3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH
3DJHRI
-DQ
3URWRFRO&ODULILFDWLRQ/HWWHU
7%$OOLDQFH3URWRFRO3D&/$Q2SHQODEHO5DQGRPL]HG)RXUSHULRG&URVVRYHU
6WXG\LQ7ZR3DQHOVRI+HDOWK\$GXOW3DUWLFLSDQWVWR$VVHVVWKH5HODWLYH%LRDYDLODELOLW\)RRG
(IIHFWDQG'RVHGHSHQGHQFHRI6LQJOH'RVH,PPHGLDWH5HOHDVHDQG6LQJOHGRVH'LVSHUVLEOH
)RUPXODWLRQVRI3UHWRPDQLG
7KHSXUSRVHRIWKLVOHWWHULVWRXSGDWHWKHFRQWDFWLQIRUPDWLRQIRUVHULRXVDGYHUVHHYHQW6$(
UHSRUWLQJ7KHVHFWLRQRISURWRFROYHUVLRQGDWHG'HFDIIHFWHGE\ WKLVFKDQJHLV
LQGLFDWHGEHORZ
3URWRFRO3DJH6HFWLRQ6HULRXV$GYHUVH(YHQW5HSRUWLQJ
&XUUHQWO\UHDGV
33'39*SKDUPDFRYLJLODQFHVHUYLFHSURYLGHUIRU7%$OOLDQFH
(PDLOUWSVDIHW\#SSGLFRP
6DIHW\+RWOLQH
6DIHW\)D[1XPEHU
$QG
$QWRQLR7RQ\/RPEDUGL0'
*OREDO$OOLDQFHIRU7%'UXJ'HYHORSPHQW
:DOO6WUHHWWK)ORRU
1HZ<RUN1<8QLWHG6WDWHVRI$PHULFD
7HOHSKRQH
0RELOH
)DFVLPLOH
(PDLO$QWRQLR/RPEDUGL&RQVXOWDQW#WEDOOLDQFHRUJ
5HYLVHGWRUHDG
7%$OOLDQFH3KDUPDFRYLJLODQFH
(PDLO$(BLQER[#WEDOOLDQFHRUJ
4XHVWLRQVUHODWLYHWR6$(FDVHSURFHVVLQJPD\DOVREHVHQWWRWKHDERYHPHQWLRQHGHPDLO
DGGUHVV,IWKHUHLVHYHUDQHPDLOIDLOXUHXSRQWU\LQJWRUHSRUWDQ6$(SOHDVHFDOO
'U/RPEDUGLDWDQGKHZLOOQRWLI\WKH6DIHW\WHDPDW7%$OOLDQFH
0HGLFDOTXHVWLRQVUHODWLYHWR$(VRU6$(VFDQEHGLUHFWHGWR
$QWRQLR7RQ\/RPEDUGL0'
*OREDO$OOLDQFHIRU7%'UXJ'HYHORSPHQW
:DOO6WUHHWWK)ORRU
1HZ<RUN1<8QLWHG6WDWHVRI$PHULFD
7HOHSKRQH
0RELOH
)DFVLPLOH
(PDLO$QWRQLR/RPEDUGL&RQVXOWDQW#WEDOOLDQFHRUJ
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 56

3URWRFRO1XPEHU3D&/
3URWRFRO&ODULILFDWLRQ/HWWHU
 
7%$OOLDQFH
3DJHRI
-DQ
$SSURYHG%\
6SRQVRU&RQWDFW
)UDQFHV3DSSDV
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH
'DWH
0HGLFDO2IILFHU
$QWRQLR7RQ\/RPEDUGL0'
7%$OOLDQFH
:DOO6WUHHWWK)ORRU
1HZ<RUN1<
3KRQH
6LJQDWXUH
'DWH
3ULQFLSDO,QYHVWLJDWRU
&\QWKLD$=DPRUD0'
:RUOGZLGH&OLQLFDO7ULDOV(DUO\3KDVH6HUYLFHV//&
1(/RRS6XLWH
6DQ$QWRQLR7H[DV
3KRQH
6LJQDWXUH
'DWH
 

		

	
Global Alliance for TB Drug Development, Protocol Pa-824-CL-011 
Appendix 16.1.1 - Page 57